




- (51) International Patent Classification:
C07K 5/062 (2006.01) C07K 5/078 (2006.01)
C07D 277/24 (2006.01) A61P 35/00 (2006.01)
- (21) International Application Number:
PCT/US20 15/059807
- (22) International Filing Date:
10 November 2015 (10.11.2015)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/077,399 10 November 2014 (10.11.2014) US
- (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

- (72) Inventors: PEREZ, Heidi L.; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). WEI, Donna D.; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). BORZILLERI, Robert M.; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). GANGWAR, Sanjeev; c/o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US). SCHROEDER, Gretchen M.; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). CHENG, Heng; c/o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US). SCHMIDT, Robert J.; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

[Continued on nextpage]

(54) Title: TUBULYSIN ANALOGS AND METHODS OF MAKING AND USE



- (57) Abstract: Tubulysin analogs of the formula (I), where R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and Y are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.

Fig. 3

TUBULYSIN ANALOGS AND METHODS OF MAKING AND USE

TECHNICAL FIELD

[0001] This invention relates to tubulysin analogs and conjugates thereof, methods for making and using them, and compositions comprising them.

5

BACKGROUND ART

[0002] The tubulysins are cytotoxins first isolated from cultures of the myxobacteria *Archangium gephyra* or *Angiococcus disciformis*, each producing a different tubulysin mixture (Sasse *et al.* 2000; Reichenbach *et al.* 1998). Their crystal structure and biosynthetic pathway have been elucidated (Steinmetz *et al.* 2004, Ullrich *et al.* 2009) and their biosynthesis genes have been sequenced (Hoeftle *et al.* 2006b). (Full citations of the references cited herein by first author or inventor and year are listed at the end of this specification.)

[0003] The tubulysins belong to a group of antimetabolic polypeptides and depsipeptides that includes the phomopsins, the dolastatins, and the cryptophycins (Hamel 2002). Other antimetabolic agents are known, for example paclitaxel, the maytansines, and the epothilones. During mitosis, a cell's microtubules reorganize to form the mitotic spindle, a process requiring the rapid assembly and disassembly of the microtubule constituent proteins α - and β -tubulin. Antimetabolic agents block this process and prevent a cell from undergoing mitosis. At the molecular level the exact blockage mechanism may differ from one antimetabolic agent to another. The tubulysins prevent the assembly of the tubulins into microtubules, causing the affected cells to accumulate in the G₂/M phase and undergo apoptosis (Khalil *et al.* 2006).

[0004] The tubulysins have a tetrapeptidyl scaffold consisting of one proteinogenic and three non-proteinogenic amino acid subunits as shown in formula (A): N-methylpipercolinic acid (Mep), isoleucine (He), tubovaline (Tuv), and either tubophenylalanine (Tup, R' equals H) or tubutyrosine (Tut, R' equals OH). Structural variations among the tubulysins (designated A, B, etc.) center around residues R', R'' and R''' of formula (A), as shown in Table I. Recently, more naturally occurring tubulysins have been isolated (Chai *et al.* 2010).

25




Table I - Naturally Occurring Tubulysins			
Tubulysin	R'	R''	R'''
A	OH	OC(=O)Me	CH ₂ OC(=O)z-Bu
B	OH	OC(=O)Me	CH ₂ OC(=O)n-Pr
C	OH	OC(=O)Me	CH ₂ OC(=O)Et
D	H	OC(=O)Me	CH ₂ OC(=O)z-Bu
E	H	OC(=O)Me	CH ₂ OC(=O)n-Pr
F	H	OC(=O)Me	CH ₂ OC(=O)Et
G	OH	OC(=O)Me	CH ₂ OC(=O)CH=CH ₂
H	H	OC(=O)Me	CH ₂ OC(=O)Me
I	OH	OC(=O)Me	CH ₂ OC(=O)Me
U	H	OC(=O)Me	H
V	H	OH	H
Y	OH	OC(=O)Me	H
Z	OH	OH	H
Pretubulysin	H	H	Me

[0005] Kaur *et al.* 2006 studied the antiproliferative properties of tubulysin A and found that it was more potent than paclitaxel and vinblastine and active in xenograft assays against various cancer cell lines. Further, tubulysin A induced apoptosis in cancer cells but not in normal cells and showed significant potential antiangiogenic properties in *in vitro* assays. The antimetabolic properties of other tubulysins have been evaluated and generally compare favorably against those of non-tubulysin antimetabolic agents (see, *e.g.*, Balasubramanian *et al.* 2009, Steinmetz *et al.* 2004, and Wipf *et al.* 2004). For these reasons, there is interest in the tubulysins as anti-cancer agents (see, *e.g.*, Domling *et al.* 2005c and Hamel 2002).

[0006] Numerous publications describe efforts directed at the synthesis of tubulysins, including: Balasubramanian *et al.* 2009, Domling *et al.* 2006, Hoefle *et al.* 2003, Neri *et al.* 2006, Peltier *et al.* 2006, Sani *et al.* 2007, Sasse *et al.* 2007, Shankar *et al.* 2009, Shibue *et al.* 2009 and 2010, and Wipf *et al.* 2004.

[0007] Disclosures of tubulysin analogs in which the natural Mep subunit was replaced by an alternative group include Patterson *et al.* 2007, Wang *et al.* 2007, Wipf *et al.* 2010, Balasubramanian *et al.* 2009, Chai *et al.* 2011, and Miao *et al.* 2013.

[0008] Several tubulysin analogs where the Ile subunit was replaced by another amino acid have been disclosed: Wipf *et al.* 2010, Vlahov *et al.* 2014a, and Zhao *et al.* 2014b.

[0009] Cong *et al.* 2014 disclose replacement of the R² acetate group in the Tub subunit with a carbamate group.

[0010] Cong *et al.* 2014 and Cheng *et al.* 2013 disclose tubulysin analogs in which the R³ group of the Tuv subunit was replaced with alternative groups. They also disclose replacing the R¹ group of the Tup/Tut subunit with an amino group, as a conjugation site.

[0011] Balasubramanian *et al.* 2008 and 2009 disclose tubulysin analogs in which the natural (1ZS)-Me group in the Tup subunit was replaced by a geminal dimethyl group in conjunction with replacement of the acetate group in the Tuv subunit with a carbonyl group.

[0012] Additional disclosures on the preparation of tubulysin analogs or derivatives include: Balasubramanian *et al.* 2008, Domling 2006, Domling *et al.* 2005a, Ellman *et al.* 2013, Hoefle *et al.* 2001 and 2006a, Pando *et al.* 2011, Patterson *et al.* 2008, Raghavan *et al.* 2008, Richter 2012a, 2012b, and 2012c, Shankar *et al.* 2013, Shibue *et al.* 2011, Sreejith *et al.* 2011, Vlahov *et al.* 2010a and 2011, Wessjohann *et al.* 2013, Wipf *et al.* 2007, Zanda *et al.* 2013, and Zhao *et al.* 2014a.


[0013] Domling *et al.* 2005 disclose conjugates of tubulysins with a partner molecule exemplified by polyethylene glycol (PEG). Other disclosures of conjugates of tubulysins are Boyd *et al.* 2008 and 2010, Jackson *et al.* 2013, Leamon *et al.* 2013, Vlahov *et al.* 2008a, 2008b, 2010b and 2014b, Leamon *et al.* 2008 and 2010, Reddy *et al.* 2009, Low *et al.* 2010, and Zhao *et al.* 2014a and 2014b. Leung *et al.* 2002 disclose polyanionic polypeptides that can be conjugated to drugs such as the tubulysins to improve their bioactivity and water solubility. Davis *et al.* 2008 and Schlupe *et al.* 2009 disclose cyclodextrin based formulations in which tubulysins are covalently attached to a cyclodextrin.

DISCLOSURE OF THE INVENTION

[0014] The present invention discloses tubulysin analogs having cytotoxic activity, which can be used as anti-cancer agents by administration as such, as a prodrug, or as a


conjugate. The analogs are characterized by, *inter alia*, a geminal dimethyl group or a cyclopropyl group positioned *alpha* to the carboxyl group of the Tup/Tut subunit.

[0015] Accordingly, in one aspect, this invention provides a compound having a structure represented by formula (I)



5

wherein



wherein

R^{1a} is H, Ci-C₅ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl, CO(Ci-C₅ alkyl), CO(C₂-C₅ alkenyl), or CO(C₂-C₅ alkynyl);

10

each R^{1b} is independently H or C₁₋₃ alkyl;

R^{1c} is H, Me, or CH(Me)₂; and

n is 0, 1, or 2;

R² is H, unsubstituted or substituted Ci-C₁₀ alkyl, unsubstituted or substituted C₂-C₁₀ alkenyl, unsubstituted or substituted C₂-C₁₀ alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted (CH₂)_{i-2}0(Ci-C₁₀ alkyl), unsubstituted or substituted (CH₂)_{i-2}0(C₂-C₁₀ alkenyl), unsubstituted or substituted (CH₂)_{i-2}0(C₂-C₁₀ alkynyl), (CH₂)_{i-2}OC(=O)(Ci-C₁₀ alkyl), unsubstituted or substituted (CH₂)_{i-2}OC(=O)(C₂-C₁₀ alkenyl), unsubstituted or substituted (CH₂)_{i-2}OC(=O)(C₂-C₁₀ alkynyl), unsubstituted or substituted C(=O)(Ci-C₁₀ alkyl), unsubstituted or substituted C(=O)(C₂-C₁₀ alkenyl), unsubstituted or substituted C(=O)(C₂-C₁₀ alkynyl), unsubstituted or substituted cycloaliphatic, unsubstituted or substituted heterocycloaliphatic, unsubstituted or substituted arylalkyl, or unsubstituted or substituted alkylaryl;


15

20


R³ is H, unsubstituted or substituted C₁-C₁₀ alkyl, unsubstituted or substituted C₂-C₁₀ alkenyl, unsubstituted or substituted C₂-C₁₀ alkynyl, unsubstituted or substituted aryl,

25

unsubstituted or substituted heteroaryl, unsubstituted or substituted (CH₂)_{i-20}(Ci-Cio alkyl), unsubstituted or substituted (CH₂)_{i-20}(C₂-Cio alkenyl), unsubstituted or substituted (CH₂)_{i-20}(C₂-Cio alkynyl), (CH₂)_{i-20}C(=O)(Ci-Cio alkyl), unsubstituted or substituted (CH₂)_{i-20}C(=O)(C₂-Cio alkenyl), unsubstituted or substituted (CH₂)_{i-20}C(=O)(C₂-Cio alkynyl), unsubstituted or substituted C(=O)(Ci-Cio alkyl), unsubstituted or substituted C(=O)(C₂-Cio alkenyl), unsubstituted or substituted C(=O)(C₂-Cio alkynyl), unsubstituted or substituted cycloaliphatic, unsubstituted or substituted heterocycloaliphatic, unsubstituted or substituted arylalkyl, unsubstituted

or substituted alkylaryl, or  ;

wherein each R^{3a} is independently H, N^{3/4}, NHMe, Cl, F, Me, Et, or CN;



wherein

R^{4a} and R^{4b} are independently H, C₁-C₅ alkyl, CH₂(C₅-C₆ cycloalkyl), CH₂C₆H₅, C₆H₅, or CH₂CH₂OH; and

W is O or S;

R⁵ and R⁶ are each Me or combine with the carbon to which they are bonded to form a cyclopropyl ring;

R⁷ is H or C₁-C₃ alkyl; and

Y is H, OH, Cl, F, CN, Me, Et, NO₂, or NH₂;

or a pharmaceutically acceptable salt thereof.

[0016] In another embodiment, this invention provides a conjugate comprising a compound of formula (I) covalently linked to a targeting moiety that specifically or preferentially binds to a chemical entity on a target cell, which target cell preferably is a cancer cell. Preferably, the targeting moiety is an antibody - more preferably a monoclonal antibody; even more preferably a human monoclonal antibody - and the chemical entity is a tumor associated antigen. The tumor associated antigen can be one that is displayed on the surface of a cancer cell or one that is secreted by a cancer cell into the surrounding extracellular space.

[0017] In another embodiment, there is provided a compound according to formula (I) covalently bonded to a linker moiety having a reactive functional group, suitable for conjugation to a targeting moiety.

[0018] In another embodiment, there is provided a method for treating a cancer in a subject suffering from such cancer, comprising administering to the subject a therapeutically effective amount of a compound of this invention or a conjugate thereof with a targeting moiety. In another embodiment, there is provided the use of a compound of this invention or a conjugate thereof with a targeting moiety for the preparation of a medicament for the treatment of cancer in a subject suffering from such cancer. A compound of this invention or a conjugate thereof with a targeting moiety can also be used to inhibit the proliferation, *in vitro* or *in vivo*, of cancer cells. Especially, the cancer can be lung cancer, gastric cancer, ovarian cancer, colon cancer, breast cancer, or renal cancer.

BRIEF DESCRIPTION OF THE DRAWING(S)

- [0019] Fig. 1 shows a scheme for the synthesis of compounds (Ia-2) and (Ia-6).
- [0020] Fig. 2 shows a scheme for the synthesis of intermediate acid 19, which is used for the synthesis of compounds (Ia-3) and (Ia-7).
- [0021] Fig. 3 shows a scheme for the synthesis of compounds (Ib-1) to (Ib-4).
- [0022] Fig. 4 shows a scheme for the synthesis of compound (Ic-1).
- [0023] Figs. 5a and 5b show, in combination, a scheme for the synthesis of compound (Ic-2).
- [0024] Fig. 6 shows a scheme for the synthesis of analog-linker compound (IIIa-2).
- [0025] Figs. 7a and 7b show, in combination, a scheme for the synthesis of analog-linker compound (IIIa-4).
- [0026] Figs. 8a and 8b show, in combination, a scheme for the synthesis of analog-linker compound (IIIc-3).

MODES FOR CARRYING OUT THE INVENTION

DEFINITIONS

- [0027] "Antibody" means whole antibodies and any antigen binding fragment (*i.e.*, "antigen-binding portion") or single chain variants thereof. A whole antibody is a protein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain comprises a heavy chain variable region (VH) and a heavy chain constant region comprising three domains, CH1, CH2 and CH3. Each light chain comprises a light chain variable region (VL or Vk) and a light chain constant region comprising

one single domain, **CL**. The **VH** and **VL** regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with more conserved framework regions (FRs). Each **VH** and **VL** comprises three CDRs and four FRs, arranged from amino- to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions contain a binding domain that interacts with an antigen. The constant regions may mediate the binding of the antibody to host tissues or factors, including various cells of the immune system (*e.g.*, effector cells) and the first component (Clq) of the classical complement system. An antibody is said to "specifically bind" to an antigen **X** if the antibody binds to antigen **X** with a **KD** of 5×10^{-8} M or less, more preferably 1×10^{-8} M or less, more preferably 6×10^{-9} M or less, more preferably 3×10^{-9} M or less, even more preferably 2×10^{-9} M or less. The antibody can be chimeric, humanized, or, preferably, human. The heavy chain constant region can be engineered to affect glycosylation type or extent, to extend antibody half-life, to enhance or reduce interactions with effector cells or the complement system, or to modulate some other property. The engineering can be accomplished by replacement, addition, or deletion of one or more amino acids or by replacement of a domain with a domain from another immunoglobulin type, or a combination of the foregoing.

[0028] "Antigen binding fragment" and "antigen binding portion" of an antibody (or simply "antibody portion" or "antibody fragment") mean one or more fragments of an antibody that retain the ability to specifically bind to an antigen. It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody, such as (i) a Fab fragment, a monovalent fragment consisting of the **VL**, **VH**, **CL** and **CH1** domains; (ii) a F(ab')₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fab' fragment, which is essentially an Fab with part of the hinge region (see, for example, Abbas *et al.*, *Cellular and Molecular Immunology*, 6th Ed., Saunders Elsevier 2007); (iv) a Fd fragment consisting of the **VH** and **CH1** domains; (v) a Fv fragment consisting of the **VL** and **VH** domains of a single arm of an antibody, (vi) a dAb fragment (Ward *et al.*, (1989) *Nature* 341:544-546), which consists of a **V_H** domain; (vii) an isolated complementarity determining region (CDR); and (viii) a nanobody, a heavy chain variable region containing a single variable domain and two constant domains. Preferred antigen binding fragments are Fab, F(ab')₂, Fab', Fv, and Fd fragments. Furthermore, although the two domains of the Fv fragment, **VL** and **VH**, are

encoded by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv, or scFv); *see, e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883.* Such single chain antibodies are also encompassed within the term "antigen-binding portion" of an antibody.

[0029] An "isolated antibody" means an antibody that is substantially free of other antibodies having different antigenic specificities (*e.g., an isolated antibody that specifically binds antigen X is substantially free of antibodies that specifically bind antigens other than antigen X*). An isolated antibody that specifically binds antigen X may, however, have cross-reactivity to other antigens, such as antigen X molecules from other species. In certain embodiments, an isolated antibody specifically binds to human antigen X and does not cross-react with other (non-human) antigen X antigens. Moreover, an isolated antibody may be substantially free of other cellular material and/or chemicals.

[0030] "Monoclonal antibody" or "monoclonal antibody composition" means a preparation of antibody molecules of single molecular composition, which displays a single binding specificity and affinity for a particular epitope.

[0031] "Human antibody" means an antibody having variable regions in which both the framework and CDR regions (and the constant region, if present) are derived from human germline immunoglobulin sequences. Human antibodies may include later modifications, including natural or synthetic modifications. Human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (*e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo*). However, "human antibody" does not include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

[0032] "Human monoclonal antibody" means an antibody displaying a single binding specificity, which has variable regions in which both the framework and CDR regions are derived from human germline immunoglobulin sequences. In one embodiment, human monoclonal antibodies are produced by a hybridoma that includes a B cell obtained from a transgenic nonhuman animal, *e.g., a transgenic mouse, having a genome comprising a human heavy chain transgene and a light chain transgene fused to an immortalized cell.*

- [0033] "Aliphatic" means a straight- or branched-chain, saturated or unsaturated, non-aromatic hydrocarbon moiety having the specified number of carbon atoms (*e.g.*, as in "C3 aliphatic," "C1-C5 aliphatic," or "Ci to C5 aliphatic," the latter two phrases being synonymous for an aliphatic moiety having from 1 to 5 carbon atoms) or, where the number of carbon atoms is not explicitly specified, from 1 to 4 carbon atoms (2 to 4 carbons in the instance of unsaturated aliphatic moieties). A similar understanding is applied to the number of carbons in other types, as in C2-4 alkene, C4-C7 cycloaliphatic, etc. In a similar vein, a term such as "(CH₂)_{i-3}" is to be understood as shorthand for the subscript being 1, 2, or 3, so that such term represents CH₂, CH₂CH₂, and CH₂CH₂CH₂.
- 10 [0034] "Alkyl" means a saturated aliphatic moiety, with the same convention for designating the number of carbon atoms being applicable. By way of illustration, C1-C4 alkyl moieties include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, *t*-butyl, 1-butyl, 2-butyl, and the like. "Alkylene" means a divalent counterpart of an alkyl group, such as CH₂CH₂, CH₂CH₂CH₂, and CH₂CH₂CH₂CH₂.
- 15 [0035] "Alkenyl" means an aliphatic moiety having at least one carbon-carbon double bond, with the same convention for designating the number of carbon atoms being applicable. By way of illustration, C2-C4 alkenyl moieties include, but are not limited to, ethenyl (vinyl), 2-propenyl (allyl or prop-2-enyl), *cis*-1-propenyl, *trans*-1-propenyl, *E*- (or *Z*-) 2-butenyl, 3-butenyl, 1,3-butadienyl (but-1,3-dienyl) and the like.
- 20 [0036] "Alkynyl" means an aliphatic moiety having at least one carbon-carbon triple bond, with the same convention for designating the number of carbon atoms being applicable. By way of illustration, C2-C4 alkynyl groups include ethynyl (acetylenyl), propargyl (prop-2-ynyl), 1-propynyl, but-2-ynyl, and the like.
- [0037] "Cycloaliphatic" means a saturated or unsaturated, non-aromatic hydrocarbon moiety having from 1 to 3 rings, each ring having from 3 to 8 (preferably from 3 to 6) carbon atoms. "Cycloalkyl" means a cycloaliphatic moiety in which each ring is saturated. "Cycloalkenyl" means a cycloaliphatic moiety in which at least one ring has at least one carbon-carbon double bond. "Cycloalkynyl" means a cycloaliphatic moiety in which at least one ring has at least one carbon-carbon triple bond. By way of illustration, cycloaliphatic moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, and adamantyl. Preferred cycloaliphatic moieties
- 25
30

are cycloalkyl ones, especially cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

"Cycloalkylene" means a divalent counterpart of a cycloalkyl group.

[0038] "Heterocycloaliphatic" means a cycloaliphatic moiety wherein, in at least one ring thereof, up to three (preferably 1 to 2) carbons have been replaced with a heteroatom independently selected from N, O, or S, where the N and S optionally may be oxidized and the N optionally may be quaternized. Similarly, "heterocycloalkyl," "heterocycloalkenyl," and "heterocycloalkynyl" means a cycloalkyl, cycloalkenyl, or cycloalkynyl moiety, respectively, in which at least one ring thereof has been so modified. Exemplary heterocycloaliphatic moieties include aziridinyl, azetidiny, 1,3-dioxanyl, oxetanyl, tetrahydrofuryl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothiopyranyl sulfone, morpholinyl, thiomorpholmyl, thiomorpholmyl sulfoxide, thiomorpholmyl sulfone, 1,3-dioxolanyl, tetrahydro-1,1-dioxothienyl, 1,4-dioxanyl, thietanyl, and the like.

"Heterocycloalkylene" means a divalent counterpart of a heterocycloalkyl group.

[0039] "Alkoxy," "aryloxy," "alkylthio," and "arylthio" mean -O(alkyl), -O(aryl), -S(alkyl), and -S(aryl), respectively. Examples are methoxy, phenoxy, methylthio, and phenylthio, respectively.

[0040] "Halogen" or "halo" means fluorine, chlorine, bromine or iodine.

[0041] "Aryl" means a hydrocarbon moiety having a mono-, bi-, or tricyclic ring system wherein each ring has from 3 to 7 carbon atoms and at least one ring is aromatic. The rings in the ring system may be fused to each other (as in naphthyl) or bonded to each other (as in biphenyl) and may be fused or bonded to non-aromatic rings (as in indanyl or cyclohexylphenyl). By way of further illustration, aryl moieties include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthracenyl, and acenaphthyl.

"Arylene" means a divalent counterpart of an aryl group, for example 1,2-phenylene, 1,3-phenylene, or 1,4-phenylene.

[0042] "Heteroaryl" means a moiety having a mono-, bi-, or tricyclic ring system wherein each ring has from 3 to 7 carbon atoms and at least one ring is an aromatic ring containing from 1 to 4 heteroatoms independently selected from from N, O, or S, where the N and S optionally may be oxidized and the N optionally may be quaternized. Such at least one heteroatom containing aromatic ring may be fused to other types of rings (as in benzofuranyl or tetrahydroisoquinolyl) or directly bonded to other types of rings (as in phenylpy-

ridyl or 2-cyclopentylpyridyl). By way of further illustration, heteroaryl moieties include pyrrolyl, furanyl, thiophenyl (thienyl), imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridyl, N-oxopyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolynyl, quinazolinyl, cinnolynyl, quinoxalinyl, naphthyridinyl, benzo-

5 furanyl, indolyl, benzothiophenyl, oxadiazolyl, thiadiazolyl, phenothiazolyl, benzimidazolyl, benzotriazolyl, dibenzofuranyl, carbazolyl, dibenzothiophenyl, acridinyl, and the like.

"Heteroarylene" means a divalent counterpart of an aryl group.

[0043] Where it is indicated that a moiety may be substituted, such as by use of "unsubstituted or substituted" or "optionally substituted" phrasing as in "unsubstituted or substituted C1-C5 alkyl" or "optionally substituted heteroaryl," such moiety may have one or

10 more independently selected substituents, preferably one to five in number, more preferably one or two in number. Substituents and substitution patterns can be selected by one of ordinary skill in the art, having regard for the moiety to which the substituent is attached, to provide compounds that are chemically stable and that can be synthesized by techniques

15 known in the art as well as the methods set forth herein.

[0044] "Arylalkyl," (heterocycloaliphatic)alkyl," "arylalkenyl," "arylalkynyl," "biarylalkyl," and the like mean an alkyl, alkenyl, or alkynyl moiety, as the case may be, substituted with an aryl, heterocycloaliphatic, biaryl, etc., moiety, as the case may be, with the open (unsatisfied) valence at the alkyl, alkenyl, or alkynyl moiety, for example as in

20 benzyl, phenethyl, N-imidazoylethyl, N-morpholinoethyl, and the like. Conversely, "alkylaryl," "alkenylcycloalkyl," and the like mean an aryl, cycloalkyl, etc., moiety, as the case may be, substituted with an alkyl, alkenyl, etc., moiety, as the case may be, for example as in methylphenyl (tolyl) or allylcyclohexyl. "Hydroxyalkyl," "haloalkyl," "alkylaryl," "cyanoaryl," and the like mean an alkyl, aryl, etc., moiety, as the case may be, substituted

25 with one or more of the identified substituent (hydroxyl, halo, etc., as the case may be).

[0045] For example, permissible substituents include, but are not limited to, alkyl (especially methyl or ethyl), alkenyl (especially allyl), alkynyl, aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, halo (especially fluoro), haloalkyl (especially trifluoromethyl), hydroxyl, hydroxyalkyl (especially hydroxyethyl), cyano, nitro, alkoxy,

30 -O(hydroxyalkyl), -O(haloalkyl) (especially -OCF₃), -O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), alkylthio, arylthio, =O, =NH, =N(alkyl), =NOH, =NO(alkyl), -C(=O)(alkyl), -C(=O)H, -CO₂H, -C(=O)NHOH, -C(=O)O(alkyl), -C(=O)O(hydroxyalkyl), -C(=O)NH₂,

-C(=O)NH(alkyl), -C(=O)N(alkyl)₂, -OC(=O)(alkyl), -OC(=O)(hydroxyalkyl),
 -OC(=O)O(alkyl), -OC(=O)O(hydroxyalkyl), -OC(=O)NH₂, -OC(=O)NH(alkyl),
 -OC(=O)N(alkyl)₂, azido, -NH₂, -NH(alkyl), -N(alkyl)₂, -NH(aryl), -NH(hydroxyalkyl),
 -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH₂, -NHC(=O)NH(alkyl), -NHC(=O)N(alkyl)₂,
 5 -NHC(=NH)NH₂, -OSO₂(alkyl), -SH, -S(alkyl), -S(aryl), -S(cycloalkyl), -S(=O)alkyl,
 -SO₂(alkyl), -SO₂NH₂, -SO₂NH(alkyl), -SO₂N(alkyl)₂, and the like.

[0046] Where the moiety being substituted is an aliphatic moiety, preferred substituents are aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, halo, hydroxyl, cyano, nitro, alkoxy, -O(hydroxyalkyl), -O(haloalkyl), -O(cycloalkyl), -O(heterocycloalkyl), -O(aryl), alkylthio,
 10 arylthio, =O, =NH, =N(alkyl), =NOH, =NO(alkyl), -CO₂H, -C(=O)NHOH, -C(=O)O(alkyl),
 -C(=O)O(hydroxyalkyl), -C(=O)NH₂, -C(=O)NH(alkyl), -C(=O)N(alkyl)₂, -OC(=O)(alkyl),
 -OC(=O)(hydroxyalkyl), -OC(=O)O(alkyl), -OC(=O)O(hydroxyalkyl), -OC(=O)NH₂,
 -OC(=O)NH(alkyl), -OC(=O)N(alkyl)₂, azido, -NH₂, -NH(alkyl), -N(alkyl)₂, -NH(aryl),
 -NH(hydroxyalkyl), -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH₂, -NHC(=O)NH(alkyl),
 15 -NHC(=O)N(alkyl)₂, -NHC(=NH)NH₂, -OSO₂(alkyl), -SH, -S(alkyl), -S(aryl), -S(=O)alkyl,
 -S(cycloalkyl), -SO₂(alkyl), -SO₂NH₂, -SO₂NH(alkyl), and -SO₂N(alkyl)₂. More preferred substituents are halo, hydroxyl, cyano, nitro, alkoxy, -O(aryl), =O, =NOH, =NO(alkyl),
 -OC(=O)(alkyl), -OC(=O)O(alkyl), -OC(=O)NH₂, -OC(=O)NH(alkyl), -OC(=O)N(alkyl)₂,
 azido, -NH₂, -NH(alkyl), -N(alkyl)₂, -NH(aryl), -NHC(=O)(alkyl), -NHC(=O)H,
 20 -NHC(=O)NH₂, -NHC(=O)NH(alkyl), -NHC(=O)N(alkyl)₂, and -NHC(=NH)NH₂.
 Especially preferred are phenyl, cyano, halo, hydroxyl, nitro, Ci-C₄alkoxy, O(C₂-C₄alkylene)OH, and O(C₂-C₄alkylene)halo.

[0047] Where the moiety being substituted is a cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl moiety, preferred substituents are alkyl, alkenyl, alkynyl, halo, haloalkyl,
 25 hydroxyl, hydroxyalkyl, cyano, nitro, alkoxy, -O(hydroxyalkyl), -O(haloalkyl), -O(aryl),
 -O(cycloalkyl), -O(heterocycloalkyl), alkylthio, arylthio, -C(=O)(alkyl), -C(=O)H, -CO₂H,
 -C(=O)NHOH, -C(=O)O(alkyl), -C(=O)O(hydroxyalkyl), -C(=O)NH₂, -C(=O)NH(alkyl),
 -C(=O)N(alkyl)₂, -OC(=O)(alkyl), -OC(=O)(hydroxyalkyl), -OC(=O)O(alkyl),
 -OC(=O)O(hydroxyalkyl), -OC(=O)NH₂, -OC(=O)NH(alkyl), -OC(=O)N(alkyl)₂, azido,
 30 -NH₂, -NH(alkyl), -N(alkyl)₂, -NH(aryl), -NH(hydroxyalkyl), -NHC(=O)(alkyl),
 -NHC(=O)H, -NHC(=O)NH₂, -NHC(=O)NH(alkyl), -NHC(=O)N(alkyl)₂, -NHC(=NH)NH₂,
 -OSO₂(alkyl), -SH, -S(alkyl), -S(aryl), -S(cycloalkyl), -S(=O)alkyl, -SO₂(alkyl), -SO₂NH₂,

-SO₂NH(alkyl), and -SO₂N(alkyl)₂. More preferred substituents are alkyl, alkenyl, halo, haloalkyl, hydroxyl, hydroxyalkyl, cyano, nitro, alkoxy, -O(hydroxyalkyl), -C(=O)(alkyl), -C(=O)H, -CO₂H, -C(=O)NHOH, -C(=O)O(alkyl), -C(=O)O(hydroxyalkyl), -C(=O)NH₂, -C(=O)NH(alkyl), -C(=O)N(alkyl)₂, -OC(=O)(alkyl), -OC(=O)(hydroxyalkyl),
5 -OC(=O)O(alkyl), -OC(=O)O(hydroxyalkyl), -OC(=O)NH₂, -OC(=O)NH(alkyl), -OC(=O)N(alkyl)₂, -NH₂, -NH(alkyl), -N(alkyl)₂, -NH(aryl), -NHC(=O)(alkyl), -NHC(=O)H, -NHC(=O)NH₂, -NHC(=O)NH(alkyl), -NHC(=O)N(alkyl)₂, and -NHC(=NH)NH₂.
Especially preferred are C1-C4 alkyl, cyano, nitro, halo, and Ci-C4alkoxy.

[0048] Where a range is stated, as in "C1-C5 alkyl" or "5 to 10%," such range includes
10 the end points of the range, as in Ci and C5 in the first instance and 5% and 10% in the second instance.

[0049] Unless particular stereoisomers are specifically indicated (e.g., by a bolded or dashed bond at a relevant stereocenter in a structural formula, by depiction of a double bond as having E or Z configuration in a structural formula, or by use stereochemistry-designating
15 nomenclature), all stereoisomers are included within the scope of the invention, as pure compounds as well as mixtures thereof. Unless otherwise indicated, individual enantiomers, diastereomers, geometrical isomers, and combinations and mixtures thereof are all encompassed by this invention.


[0050] Those skilled in the art will appreciate that compounds may have tautomeric
20 forms (e.g., keto and enol forms), resonance forms, and zwitterionic forms that are equivalent to those depicted in the structural formulae used herein and that the structural formulae encompass such tautomeric, resonance, or zwitterionic forms.

[0051] "Pharmaceutically acceptable ester" means an ester that hydrolyzes *in vivo* (for
25 example in the human body) to produce the parent compound or a salt thereof or has *per se* activity similar to that of the parent compound. Suitable esters include C1-C5 alkyl, C₂-C₅ alkenyl or C₂-C₅ alkynyl esters, especially methyl, ethyl or n-propyl.


[0052] "Pharmaceutically acceptable salt" means a salt of a compound suitable for
30 pharmaceutical formulation. Where a compound has one or more basic groups, the salt can be an acid addition salt, such as a sulfate, hydrobromide, tartrate, mesylate, maleate, citrate, phosphate, acetate, pamoate (embonate), hydroiodide, nitrate, hydrochloride, lactate, methyl-sulfate, fumarate, benzoate, succinate, mesylate, lactobionate, suberate, tosylate, and the like.

Where a compound has one or more acidic groups, the salt can be a salt such as a calcium salt, potassium salt, magnesium salt, meglumine salt, ammonium salt, zinc salt, piperazine salt, tromethamine salt, lithium salt, choline salt, diethylamine salt, 4-phenylcyclohexylamine salt, benzathine salt, sodium salt, tetramethylammonium salt, and the like. Polymorphic crystalline forms and solvates are also encompassed within the scope of this invention.

[0053] In the formulae of this specification, a wavy line transverse to a bond denotes a covalent attachment site. For instance, a statement that R is




[0054] In the formulae of this specification, a bond traversing a phenyl ring between two carbons thereof means that the group attached to the bond may be located at any of the *ortho*, *meta*, or *para* positions of the phenyl ring. By way of illustration, the formula




ANALOGS


[0055] In one embodiment of tubulysin analogs according to formula (I)




15




[0056] In another preferred embodiment of analogs according to formula (I), R¹ is



[0057] Preferably one of R^{3a} and Y is NH_2 in formula (I) when R^1 is



[0058] Also in formula (I), preferred groups $N(R^{4a})(R^{4b})$ are:




10 [0059] In another preferred embodiment of compounds according to formula (I), R^5 and R^6 are each Me.

[0060] In the definitions of R^2 and R^3 in formula (I), where a group is defined as being either unsubstituted or substituted, it preferably is unsubstituted.

15 [0061] The synthesis of tubulysin analogs with various groups at the R^3 , R^4 , R^7 , and Y positions of formula (I) is taught by Cheng *et al.* 2013 and Cong *et al.* 2014, the disclosures of which are incorporated herein by reference. The techniques disclosed there for the synthesis of structural variants at those positions are applicable to the compounds of this invention, *mutatis mutandis*.


20 [0062] In one preferred embodiment, a compound of formula (I) has a structure represented by formula (Ia)




wherein R^2 is Me, Et, $CH_2CH_2CH_3$, $CH(Me)_2$, $CH(Et)_2$, or ;

R^3 is H, Ci-C₅ alkyl, Ci-C₅ alkenyl, Ci-C₅ alkynyl, CH₂OC(=O)Ci-C₅ alkyl, CH₂OC(=O)Ci-C₅ alkenyl, or CH₂OC(=O)Ci-C₅ alkynyl; and R^4 , R^5 , R^6 and R^7 are as defined in respect formula (I).


[0063] A preferred compound according to formula (Ia) has a structure represented by
5 formula (Ia')



[0064] Another preferred compound according to formula (Ia) has a structure represented
by formula (Ib')




10 [0065] In formulae (Ia') and (Ib'), R^2 is CH(Me)₂, CH(Et)₂, or




; R^3 is Ci-5 alkyl; R^{4d} is Me or NHMe; and R^7 is H, Me, or Et.

[0066] In yet another preferred embodiment, a compound of formula (I) has a structure
represented by formula (Ic):




15 wherein





R² is CH(Me)₂, CH(Et)₂, or  ;








R³ is Ci-5 alkyl; R^{4d} is Me or NHMe; R⁵ and R⁶ are each Me or combine with the carbon to which they are bonded to form a cyclopropyl ring; and R⁷ is H, Me, or Et. Preferably, R⁵ and

R⁶ are each Me and R¹ is .


- 5 [0067] Specific examples of compounds of this invention wherein, in formula (I), R⁵ and R⁶ are both methyl and R¹ is

 are shown following:




Compound	R ²⁰	R ²¹	R ²²
(Ia-1)			NH ₂
(Ia-2)			NH ₂
(Ia-3)			NH ₂
(Ia-4)			NH ₂
(Ia-5)			NO ₂
(Ia-6)			NO ₂
(Ia-7)			NO ₂

[0068] Specific examples of compounds of this invention wherein, in formula (I), R⁵ and R⁶ combine with the carbon to which they are bonded to form a cyclopropyl ring and R¹ is




are shown following:




Compound	R ²³	R ²⁴
(Ib-1)	NH ₂	H
(Ib-2)	NH ₂	Me
(Ib-3)	NO ₂	H
(Ib-4)	NO ₂	Me

5

[0069] Specific examples of compounds of this invention wherein, in formula (I), R⁵ and R⁶ are both Me and R¹ is




are shown following:



(Ic⁻1)

10



(Ic⁻2)

CONJUGATES

General

[0070] Optionally, compounds of this invention can be conjugated to a targeting moiety that specifically or preferentially binds to a chemical entity on a cancer cell. Preferably, the targeting moiety is an antibody or antigen binding portion thereof and the chemical entity is a tumor associated antigen. For a review on the mechanism of action and use of ADCs in cancer therapy, see Schrama *et al.* 2006.

[0071] Thus, another embodiment of this invention is a conjugate comprising cytotoxic compound according to this invention and a ligand, represented by formula (II)



where Z is a ligand, D is a tubulysin analog of this invention, and $-(X^D)_aC(X^Z)_b-$ are collectively referred to as a "linker moiety" or "linker" because they link Z and D. Within the linker, C is a cleavable group designed to be cleaved at or near the site of intended biological action of compound D; X^D and X^Z are referred to as spacer moieties (or "spacers") because they space apart D and C and C and Z, respectively; subscripts a, b, and c are independently 0 or 1 (that is, the presence of X^D , X^Z and C are optional). Subscript m is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (preferably 1, 2, 3, or 4). D, X^D , C, X^Z and Z are more fully described hereinbelow.

[0072] Ligand Z - for example an antibody - performs a targeting function. By binding to a target tissue or cell where its antigen or receptor is located, ligand Z directs the conjugate there. (When ligand Z is an antibody, the conjugate is sometimes referred to as antibody-drug conjugate (ADC) or an immunoconjugate. Preferably, the target tissue or cell is a cancer tissue or cell and the antigen or receptor is a tumor-associated antigen, that is, an antigen that is uniquely expressed by cancerous cells or is overexpressed by cancer cells, compared to non-cancerous cells. Cleavage of group C at the target tissue or cell releases compound D to exert its cytotoxic effect locally. In some instances, the conjugate is internalized into a target cell by endocytosis and cleavage takes place within the target cell. In this manner, precise delivery of compound D is achieved at the site of intended action, reducing the dosage needed. Also, compound D is normally biologically inactive (or significantly less active) in its conjugated state, thereby reducing undesired toxicity against non-target tissue or cells. As anticancer drugs are often highly toxic to cells in general, this is an important consideration.

[0073] As reflected by the subscript m , each molecule of ligand Z can conjugate with more than one compound D, depending on the number of sites ligand Z has available for conjugation and the experimental conditions employed. Those skilled in the art will appreciate that, while each individual molecule of ligand Z is conjugated to an integer
5 number of compounds D, a preparation of the conjugate may analyze for a non-integer ratio of compounds D to ligand Z, reflecting a statistical average. This ratio is referred to as the substitution ratio (SR) or, alternatively, the drug-antibody ratio (DAR).

Ligand Z

[0074] Preferably, ligand Z is an antibody. For convenience and brevity and not by way
10 of limitation, the detailed subsequent discussion herein about the conjugation of ligand Z is written in the context of its being an antibody, but those skilled in the art will understand that other types of ligand Z can be conjugated, *mutatis mutandis*. For example, conjugates with folic acid as the ligand can target cells having the folate receptor on their surfaces (Vlahov *et al.* 2008; Leamon *et al.* 2008). For the same reason, the detailed discussion below is
15 primarily written in terms of a 1:1 ratio of antibody Z to analog D ($m = 1$).

[0075] Preferably, ligand Z is an antibody against a tumor associated antigen, allowing the selective targeting of cancer cells. Examples of such antigens include: mesothelin, prostate specific membrane antigen (PSMA), CD19, CD22, CD30, CD70, B7H4 (also known as 08E), protein tyrosine kinase 7 (PTK7), glypican-3, RG1, CTLA-4, and CD44. The
20 antibody can be animal (*e.g.*, murine), chimeric, humanized, or, preferably, human. The antibody preferably is monoclonal, especially a monoclonal human antibody. The preparation of human monoclonal antibodies against some of the aforementioned antigens is disclosed in Korman *et al.*, US 2009/0074660 A1 (B7H4); Rao-Naik *et al.*, 8,097,703 B2 (CD19); King
et al., US 2010/0143368 A1 (CD22); Keler *et al.*, US 7,387,776 B2 (2008) (CD30); Terrett *et al.*, US 8,124,738 B2 (CD70); Korman *et al.*, US 6,984,720 B1 (2006) (CTLA-4); Korman *et al.*, US 8,008,449 B2 (2011) (PD-1); Huang *et al.*, US 2009/0297438 A1 and Cardarelli *et al.*, US 7,875,278 B2 (PSMA); Terrett *et al.*, US 2010/0034826 A1 (PTK7); Terrett *et al.*, US
25 2010/0209432 (A1) (glypican-3); Harkins *et al.*, US 7,335,748 B2(2008) (RG1); Terrett *et al.*, US 8,268,970 B2 (2012) (mesothelin); and Xu *et al.*, US 2010/0092484 A1 (CD44); the
30 disclosures of which are incorporated herein by reference.

[0076] Ligand Z can also be an antibody fragment or antibody mimetic, such as an affibody, a domain antibody (dAb), a nanobody, a unibody, a DARPin, an anticalin, a versabody, a duocalin, a lipocalin, or an avimer.

[0077] Any one of several different reactive groups on ligand Z can be a conjugation site, including ϵ -amino groups in lysine residues, pendant carbohydrate moieties, carboxylic acid groups, disulfide groups, and thiol groups. Each type of reactive group represents a trade-off, having some advantages and some disadvantages. For reviews on antibody reactive groups suitable for conjugation, see, e.g., Garnett, *Adv. Drug Delivery Rev.* 53 (2001), 171-216 and Dubowchik and Walker, *Pharmacology & Therapeutics* 83 (1999), 67-123, the disclosures of which are incorporated herein by reference.

[0078] In one embodiment, ligand Z is conjugated via a lysine ϵ -amino group. Most antibodies have multiple lysine ϵ -amino groups, which can be conjugated via amide, urea, thiourea, or carbamate bonds using techniques known in the art. However, it is difficult to control which and how many ϵ -amino groups react, leading to potential batch-to-batch variability in conjugate preparations. Also, conjugation may cause neutralization of a protonated ϵ -amino group important for maintaining the antibody's native conformation or may take place at a lysine near or at the antigen binding site, neither being a desirable occurrence.

[0079] In another embodiment, ligand Z can be conjugated via a carbohydrate side chain, as many antibodies are glycosylated. The carbohydrate side chain can be oxidized with periodate to generate aldehyde groups, which in turn can be reacted with amines to form an imine group, such as in a semicarbazone, oxime, or hydrazone. If desired, the imine group can be converted to a more stable amine group by reduction with sodium cyanoborohydride. For additional disclosures on conjugation via carbohydrate side chains, see, e.g., Rodwell *et al.*, *Proc. Nat'l Acad. Sci. USA* 83, 2632-2636 (1986); the disclosure of which is incorporated herein by reference. As with lysine ϵ -amino groups, there are concerns regarding reproducibility of the location of the conjugation site(s) and stoichiometry.

[0080] In yet another embodiment, ligand Z can be conjugated via a carboxylic acid group. In one embodiment, a terminal carboxylic acid group is functionalized to generate a carbohydrazide, which is then reacted with an aldehyde-bearing conjugation moiety. See Fisch *et al.*, *Bioconjugate Chemistry* 1992, 3, 147-153.

[0081] In yet another embodiment, antibody Z can be conjugated via a disulfide group bridging a cysteine residue on antibody Z and a sulfur on the other portion of the conjugate. Some antibodies lack free thiol (sulfhydryl) groups but have disulfide groups, for example in the hinge region. In such case, free thiol groups can be generated by reduction of native
5 disulfide groups. The thiol groups so generated can then be used for conjugation. See, e.g., Packard *et al*, *Biochemistry* **1986**, 25, 3548-3552; King *et al*, *Cancer Res.* 54, 6176-6185 (1994); and Doronina *et al*, *Nature Biotechnol* 21(7), 778-784 (2003); the disclosures of which are incorporated herein by reference. Again, there are concerns regarding conjugation site location and stoichiometry and the possible disruption of antibody native conformation.

[0082] A number of methods are known for introducing free thiol groups into antibodies without breaking native disulfide bonds, which methods can be practiced with a ligand Z of this invention. Depending on the method employed, it may be possible to introduce a predictable number of free sulfhydryls at predetermined locations. In one approach, mutated antibodies are prepared in which a cysteine is substituted for another amino acid. See, for
15 example, Eigenbrot *et al*, US 7,521,541 B2 (2009); Chilkoti *et al*, *Bioconjugate Chem.* **1994**, 5, 504-507; Urnovitz *et al*, US 4,698,420 (1987); Stimmel *et al*, *J. Biol. Chem.*, 275 (39), 30445-30450 (2000); Bam *et al*, US 7,31 1,902 B2 (2007); Kuan *et al.*, *J. Biol. Chem.*, 269 (10), 7610-7618 (1994); Poon *et al.*, *J. Biol. Chem.*, 270 (15), 8571-8577 (1995). In another approach, an extra cysteine is added to the C-terminus. See, e.g. Cumber *et al.*, *J.*
20 *Immunol*, 149, 120-126 (1992); King *et al*, *Cancer Res.*, 54, 6176-6185 (1994); Li *et al*, *Bioconjugate Chem.*, 13, 985-995 (2002); Yang *et al*, *Protein Engineering*, 16, 761-770 (2003); and Olafson *et al*, *Protein Engineering Design & Selection*, 17, 21-27 (2004). A preferred method for introducing free cysteines is that taught by Liu *et al*, WO 2009/026274 A1, in which a cysteine bearing amino acid sequence is added to the C-terminus of the heavy
25 chain of an antibody. This method introduces a known number of cysteine residues (one per heavy chain) at a known location away from the antigen binding site. The disclosures of the documents cited in this paragraph are all incorporated herein by reference.

[0083] In yet another embodiment, lysine ϵ -amino groups can be modified with reagents such as 2-iminothiolane or N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), converting
30 an ϵ -amino group into a thiol or disulfide group - creating a cysteine surrogate, as it were. However, this method suffers from the same conjugation location and stoichiometry limitations associated with ϵ -amino groups proper.

Linker Components

[0084] As noted above, the linker portion of a conjugate of this invention comprises up to three elements: a cleavable group C and optional spacers X^Z and X^D.

[0085] Cleavable group C is a group cleavable under physiological conditions, preferably selected such that it is relatively stable while the conjugate is in general circulation in the blood plasma, but is readily cleaved once the conjugate reaches its site of intended action, that is, near, at, or within the target cell. Preferably, the conjugate is internalized by a target cell upon binding of antibody Z to an antigen displayed on the surface of the target cell. Subsequently, cleavage of group C occurs in a vesicular body of the target cell (an early endosome, a late endosome, or, especially, a lysosome).

[0086] In one embodiment, group C is a pH sensitive group. The pH in blood plasma is slightly above neutral, while the pH inside a lysosome is acidic, circa 5. Thus, a group C whose cleavage is acid catalyzed will cleave at a rate several orders of magnitude faster inside a lysosome than in the blood plasma rate. Examples of suitable acid-sensitive groups include cis-aconityl amides and hydrazones, as described in Shen *et al.*, US 4,631,190 (1986); Shen *et al.*, US 5,144,011 (1992); Shen *et al.*, *Biochem. Biophys. Res. Commun.* 102, 1048-1054 (1981) and Yang *et al.*, *Proc. Natl Acad. Sci (USA)*, 85, 1189-1193 (1988); the disclosures of which are incorporated herein by reference.

[0087] In another embodiment, group C is a disulfide. Disulfides can be cleaved by a thiol-disulfide exchange mechanism, at a rate dependent on the ambient thiol concentration. As the intracellular concentration of glutathione and other thiols is higher than their serum concentrations, the cleavage rate of a disulfide will be higher intracellularly. Further, the rate of thiol-disulfide exchange can be modulated by adjustment of the steric and electronic characteristics of the disulfide (e.g., an alkyl-aryl disulfide versus an alkyl-alkyl disulfide; substitution on the aryl ring, etc.), enabling the design of disulfide linkages that have enhanced serum stability or a particular cleavage rate. For additional disclosures relating to disulfide cleavable groups in conjugates, see, e.g., Thorpe *et al.*, *Cancer Res.* 48, 6396-6403 (1988); Santi *et al.*, US 7,541,530 B2 (2009); Ng *et al.*, US 6,989,452 B2 (2006); Ng *et al.*, WO 2002/096910 A1; Boyd *et al.*, US 7,691,962 B2; and Sufi *et al.*, US 2010/0145036 A1; the disclosures of which are incorporated herein by reference.

[0088] A preferred cleavable group is a peptide that is cleaved selectively by a protease inside the target cell, as opposed to by a protease in the serum. Typically, a cleavable peptide group comprises from 1 to 20 amino acids, preferably from 1 to 6 amino acids, more preferably from 1 to 3 amino acids. The amino acid(s) can be natural and/or non-natural α -amino acids. Natural amino acids are those encoded by the genetic code, as well as amino acids derived therefrom, *e.g.*, hydroxyproline, γ -carboxyglutamate, citrulline, and O-phosphoserine. In this context, the term "amino acid" also includes amino acid analogs and mimetics. Analogous are compounds having the same general $H_2N(R)CHCO_2H$ structure of a natural amino acid, except that the R group is not one found among the natural amino acids. Examples of analogs include homoserine, norleucine, methionine-sulfoxide, and methionine methyl sulfonium. An amino acid mimetic is a compound that has a structure different from the general chemical structure of an α -amino acid but functions in a manner similar to one. The amino acid can be of the "L" stereochemistry of the genetically encoded amino acids, as well as of the enantiomeric "D" stereochemistry.

[0089] Preferably, group C contains an amino acid sequence that is a cleavage recognition sequence for a protease. Many cleavage recognition sequences are known in the art. *See, e.g.,* Matayoshi *et al. Science* 247: 954 (1990); Dunn *et al. Meth. Enzymol.* 241 : 254 (1994); Seidah *et al. Meth. Enzymol.* 244: 175 (1994); Thornberry, *Meth. Enzymol.* 244: 615 (1994); Weber *et al. Meth. Enzymol.* 244: 595 (1994); Smith *et al. Meth. Enzymol.* 244: 412 (1994); and Bouvier *et al. Meth. Enzymol.* 248: 614 (1995); the disclosures of which are incorporated herein by reference.

[0090] For conjugates that are not intended to be internalized by a cell, a group C can be chosen such that it is cleaved by a protease present in the extracellular matrix in the vicinity of the target tissue, *e.g.*, a protease released by nearby dying cells or a tumor-associated protease. Exemplary extracellular tumor-associated proteases are matrix metalloproteases (MMP), thimet oligopeptidase (TOP) and CD10.

[0091] For conjugates that are designed to be internalized by a cell, group C preferably comprises an amino acid sequence selected for cleavage by an endosomal or lysosomal protease, especially the latter. Non-limiting examples of such proteases include cathepsins B, C, D, H, L and S, especially cathepsin B. Cathepsin B preferentially cleaves peptides at a sequence $-AA^2-AA^1-$ where AA^1 is a basic or strongly hydrogen bonding amino acid (such as lysine, arginine, or citrulline) and AA^2 is a hydrophobic amino acid (such as phenylalanine,

valine, alanine, leucine, or isoleucine), for example Val-Cit (where Cit denotes citrulline) or Val-Lys. (Herein, amino acid sequences are written in the N-to-C direction, as in $H_2N-AA^2-AA^1-CO_2H$, unless the context clearly indicates otherwise.) Lys-Val-Ala, Asp-Val-Ala, Val-Ala, Lys-Val-Cit, and Asp-Val-Cit are also substrate peptide motifs for cathpsin B, although in some instances the cleavage rate may be slower. For additional information regarding cathepsin-cleavable groups, see Dubowchik *et al*, *Bioorg. Med. Chem. Lett.* **8**, 3341-3346 (1998); Dubowchik *et al*, *Bioorg. Med. Chem. Lett.*, **8** 3347-3352 (1998); and Dubowchik *et al*, *Bioconjugate Chem.* **13**, 855-869 (2002); the disclosures of which are incorporated by reference. Another enzyme that can be utilized for cleaving peptidyl linkers is legumain, a lysosomal cysteine protease that preferentially cleaves at Ala-Ala-Asn.

[0092] In one embodiment, Group C is a peptide comprising a two-amino acid sequence $-AA^2-AA^1-$ wherein AA^1 is lysine, arginine, or citrulline and AA^2 is phenylalanine, valine, alanine, leucine or isoleucine. In another embodiment, C consists of a sequence of one to three amino acids, selected from the group consisting of Val-Cit, Ala-Val, Val-Ala-Val, Lys-Lys, Ala-Asn-Val, Val-Leu-Lys, Cit-Cit, Val-Lys, Ala-Ala-Asn, Lys, Cit, Ser, and Glu.


[0093] The preparation and design of cleavable groups C consisting of a single amino acid is disclosed in Chen *et al*, US 2010/01 13476 A1, the disclosure of which is incorporated herein by reference.

[0094] Group C can also be a photocleavable one, for example a nitrobenzyl ether that is cleaved upon exposure to light.


[0095] Group C can be bonded directly to antibody Z or analog D; *i.e.* spacers X^Z and X^D , as the case may be, can be absent. For example, if group C is a disulfide, one of the two sulfurs can be a cysteine residue or its surrogate on antibody Z. Or, group C can be a hydrazone bonded to an aldehyde on a carbohydrate side chain of the antibody. Or, group C can be a peptide bond formed with a lysine ϵ -amino group of antibody Z. In a preferred embodiment, compound D is directly bonded to group C via a peptidyl bond to a carboxyl or amine group in compound D.

[0096] When present, spacer X^Z provides spatial separation between group C and antibody Z, lest the former sterically interfere with antigen binding by latter or the latter sterically interfere with cleavage of the former. Further, spacer X^Z can be used to confer increased solubility or decreased aggregation properties to conjugates. A spacer X^Z can

comprise one or more modular segments, which can be assembled in any number of combinations. Examples of suitable segments for a spacer X^Z are:



where the subscript g is 0 or 1 and the subscript h is 1 to 24, preferably 2 to 4. These segments can be combined, such as illustrated below:




[0097] Spacer X^D, if present, provides spatial separation between group C and compound D, lest the latter interfere sterically or electronically with cleavage of the former. Spacer X^D also can serve to introduce additional molecular mass and chemical functionality into a conjugate. Generally, the additional mass and functionality will affect the serum half-life and other properties of the conjugate. Thus, through judicious selection of spacer groups, the serum half-life of a conjugate can be modulated. Spacer X^D also can be assembled from modular segments, as described above in the context of spacer X^Z.

[0098] Spacers X^Z and/or X^D, where present, preferably provide a linear separation of from 4 to 25 atoms, more preferably from 4 to 20 atoms, between Z and C or D and C, respectively.

[0099] The linker can perform other functions in addition to covalently linking the antibody and the drug. For instance, the linker can contain poly(ethylene glycol) (PEG) groups, which enhance solubility either during the performance the conjugation chemistry or in the final ADC product. Where a PEG group is present, it may be incorporated into either spacer X^Z of X^D, or both. The number of repeat units in a PEG group can be from 2 to 20, preferably between 4 and 10.

[00100] Either spacer X^Z or X^D , or both, can comprise a self-immolating moiety. A self-immolating moiety is a moiety that (1) is bonded to group C and either antibody Z or cytotoxin D and (2) has a structure such that cleavage from group C initiates a reaction sequence resulting in the self-immolating moiety disbonding itself from antibody Z or cytotoxin D, as the case may be. In other words, reaction at a site distal from antibody Z or cytotoxin D (cleavage from group C) causes the X^Z -Z or the X^D -D bond to rupture as well. The presence of a self-immolating moiety is desirable in the case of spacer X^D because, if, after cleavage of the conjugate, spacer X^D or a portion thereof were to remain attached to cytotoxin D, the biological activity of the latter may be impaired. The use of a self-immolating moiety is especially desirable where cleavable group C is a polypeptide, in which instance the self-immolating moiety typically is located adjacent thereto.

[00101] Exemplary self-immolating moieties (i)-(v) bonded to a hydroxyl or amino group on a partner molecule D are shown below:



[00102] The self-immolating moiety is the structure between dotted lines a and b, with adjacent structural features shown to provide context. Self-immolating moieties (i) and (v) are bonded to a compound $D-NH_2$ (i.e., compound D is conjugated via an amino group),

while self-immolating moieties (ii), (iii), and (iv) are bonded to a compound D-OH (i.e., compound D is conjugated via a hydroxyl or carboxyl group). Cleavage of the amide bond at dotted line b (e.g., by a peptidase) releases the amide nitrogen as an amine nitrogen, initiating a reaction sequence that results in the cleavage of the bond at dotted line a and the consequent release of D-OH or D-NH₂, as the case may be. Alternatively, the cleavage that triggers the self-immolating reaction can be by a different type of enzyme, for example by a β-glucuronidase, as in the instance of structure (vi). For additional disclosures regarding self-immolating moieties, see Carl *et al.*, *J. Med. Chem.*, 24 (3), 479-480 (1981); Carl *et al.*, WO 81/01 145 (1981); Dubowchik *et al.*, *Pharmacology & Therapeutics*, **83**, 67-123 (1999); Firestone *et al.*, US 6,214,345 B1 (2001); Toki *et al.*, *J. Org. Chem.* **67**, 1866-1872 (2002); Doronina *et al.*, *Nature Biotechnology* **21** (7), 778-784 (2003) (*erratum*, p. 941); Boyd *et al.*, US 7,691,962 B2; Boyd *et al.*, US 2008/0279868 A1; Sufi *et al.*, WO 2008/083312 A2; Feng, US 7,375,078 B2; Jeffrey *et al.*, US 8039,273; and Senter *et al.*, US 2003/0096743 A1; the disclosures of which are incorporated by reference. A preferred self-immolating group is /?-aminobenzyl oxycarbonyl (PABC) group, as shown in structure (i).


[00103] In another embodiment, an antibody targeting moiety and the cytotoxic compound D are linked by a non-cleavable linker, i.e., element C is absent. Degradation of the antibody eventually reduces the linker to a small appended moiety that does not interfere with the biological activity of cytotoxic compound D.

20 Conjugation Techniques


[00104] Conjugates of this invention preferably are made by first preparing a compound comprising an analog of this invention (represented by D in the formulae below) and linker (X^D)_a(C)_c(X^Z)_b (where X^D, C, X^Z, a, b, and c are as defined for formula (II)) to form an analog-linker composition represented by formula (III):



where R³¹ is a functional group suitable for reacting with a complementary functional group on antibody Z to form the conjugate. Examples of suitable groups R³¹ include amino, azide, cyclooctyne,



reacted with 2-iminothiolane to introduce a free thiol (-SH) group. The thiol group can react with a maleimide or other nucleophile acceptor group to effect conjugation:




5

[00111] Typically, a thiolation level of two to three thiols per antibody is achieved. For a representative procedure, see Cong *et al.* 2014, the disclosure of which is incorporated herein by reference. Thus, in one embodiment, an antibody for conjugation to a tubulysin analog of this invention has one or more lysine residues (preferably two or three) modified by reaction with iminothiolane.


[00112] An -SH group can also be used for conjugation where the antibody has been modified to introduce a maleimide group thereto, in a Michael addition reaction that is the "mirror image" of that described above. Antibodies can be modified to have maleimide groups with N-succinimidyl 4-(maleimidomethyl)-cyclohexanecarboxylate (SMCC) or its sulfonated variant sulfo-SMCC, both reagents being available from Sigma-Aldrich.

[00113] An alternative conjugation technique employs copper-free "click chemistry," in which an azide group adds across the strained alkyne bond of a cyclooctyne to form an 1,2,3-triazole ring. See, *e.g.*, Agard *et al.*, *J. Amer. Chem. Soc.* **2004**, *126*, 15046; Best, *Biochemistry* **2009**, *48*, 6571, the disclosures of which are incorporated herein by reference. The azide can be located on the antibody and the cyclooctyne on the drug moiety, or vice-versa. A preferred cyclooctyne group is dibenzocyclooctyne (DIBO). Various reagents having a DIBO group are available from Invitrogen/Molecular Probes, Eugene, Oregon. The reaction below illustrates click chemistry conjugation for the instance in which the DIBO group is attached to the antibody (Ab):




[00114] Yet another conjugation technique involves introducing a non-natural amino acid into an antibody, with the non-natural amino acid providing a functionality for conjugation with a reactive functional group in the drug moiety. For instance, the non-natural amino acid p-acetylphenylalanine can be incorporated into an antibody or other polypeptide, as taught in Tian *et al.*, WO 2008/030612 A2 (2008). The ketone group in p-acetylphenylalanine can be a conjugation site via the formation of an oxime with a hydroxylamino group on the linker-drug moiety. Alternatively, the non-natural amino acid p-azidophenylalanine can be incorporated into an antibody to provide an azide functional group for conjugation via click chemistry, as discussed above. Non-natural amino acids can also be incorporated into an antibody or other polypeptide using cell-free methods, as taught in Goerke *et al.*, US 2010/0093024 A1 (2010) and Goerke *et al.*, *Biotechnol. Bioeng.* **2009**, 102 (2), 400-416. The foregoing disclosures are incorporated herein by reference. Thus, in one embodiment, an antibody that is used for making a conjugate with a tubulysin of this invention has one or more amino acids replaced by a non-natural amino acid, which preferably is p-acetylphenylalanine or p-azidophenylalanine, more preferably p-acetylphenylalanine.

[00115] Still another conjugation technique uses the enzyme transglutaminase (preferably bacterial transglutaminase or BTG), per Jeger *et al.*, *Angew. Chem. Int. Ed.* **2010**, 49, 9995. BTG forms an amide bond between the side chain carboxamide of a glutamine (the amine acceptor) and an alkyleneamino group (the amine donor), which can be, for example, the ϵ -amino group of a lysine or a 5-amino-n-pentyl group. In a typical conjugation reaction, the glutamine residue is located on the antibody, while the alkyleneamino group is located on the linker-drug moiety, as shown below:



25



Conjugate

[00116] The positioning of a glutamine residue on a polypeptide chain has a large effect on its susceptibility to BTG mediated transamidation. None of the glutamine residues on an antibody are normally BTG substrates. However, if the antibody is deglycosylated - the glycosylation site being asparagine 297 (N297) - nearby glutamine 295 (Q295) is rendered BTG susceptible. An antibody can be deglycosylated enzymatically by treatment with PNGase F (Peptide-N-Glycosidase F). Alternatively, an antibody can be synthesized glycoside free by introducing an N297A mutation in the constant region, to eliminate the N297 glycosylation site. Further, it has been shown that an N297Q substitution in an antibody not only eliminates glycosylation, but also introduces a second glutamine residue (at position 297) that too is an amine acceptor. Thus, in one embodiment, an antibody that is conjugated to a tubulysin analog of this invention is deglycosylated. In another embodiment, the antibody has an N297Q substitution. Those skilled in the art will appreciate that deglycosylation by post-synthesis modification or by introducing an N297A mutation generates two BTG-reactive glutamine residues per antibody (one per heavy chain, at position 295), while an antibody with an N297Q substitution will have four BTG-reactive glutamine residues (two per heavy chain, at positions 295 and 297).

[00117] Conjugation can also be effected using the enzyme Sortase A, as taught in Levary *et al*, *PLoS One* **2011**, 6(4), e18342; Proft, *Biotechnol. Lett.* **2010**, 32, 1-10; Ploegh *et al*, WO 2010/087994 A2 (2010); and Mao *et al.*, WO 2005/05 1976 A2 (2005). The Sortase A recognition motif (typically LPXTG, where X is any natural amino acid) may be located on the ligand Z and the nucleophilic acceptor motif (typically GGG) may be the group R³¹ in formula (III), or vice-versa.


[00118] An antibody also can be adapted for conjugation by modifying its glycosyl group to introduce a keto group that serves as a conjugation site by oxime formation, as taught by Zhu *et al*, *mAbs* **2014**, 6, 1. In another glycoengineering variation, an antibody's glycosyl group can be modified to introduce an azide group for conjugation by "click chemistry." See Huang *et al*, *J. Am. Chem. Soc.* **2012**, 134, 12308 and Wang, US 8,900,826 B2 (2014) and US 7,807,405 B2 (2010).

[00119] Yet another conjugation technique can be generally referred to as disulfide bridging: the disulfide bonds in an antibody are cleaved, creating a pair of thiol (-SH) groups. The antibody is then treated with a drug-linker compound that contains two thiol-reactive sites. Reaction of the thiol groups with the two sites effects a re-bridging that re-creates, in a fashion, the original disulfide bridge, thus preserving the antibody tertiary structure and attaching a drug-linker moiety. See, *e.g.*, Burt *et al.*, WO 2013/190292 A2 (2013) and Jackson *et al.*, US 2013/0224228 A1 (2013).

Analog-Linker Compounds


[00120] Generally, an ADC of a tubulysin analog of this invention comprises a linker attached at one end thereof to an amine group located at a modified Mep, Tuv, or Tup subunit (preferably a modified Mep or Tup subunit). The linker is attached at the other end thereof to the antibody. Reflecting the diversity of conjugation techniques available, the tubulysin analogs of this invention can be elaborated into many different tubulysin analog-linker compounds suitable for conjugation to an antibody.

[00121] A preferred tubulysin analog-linker compound has a structure represented by formula (IIia):



or a pharmaceutically acceptable salt thereof;

wherein

R^2 is Me, Et, $\text{CH}_2\text{CH}_2\text{CH}_3$, $\text{CH}(\text{Me})_2$, $\text{CH}(\text{Et})_2$, or  ;

preferably $\text{CH}(\text{Me})_2$, $\text{CH}(\text{Et})_2$, or  ;

R^3 is H, $\text{C}_1\text{-C}_5$ alkyl, $\text{C}_1\text{-C}_5$ alkenyl, $\text{C}_1\text{-C}_5$ alkynyl, $\text{CH}_2\text{OC}(=\text{O})\text{C}_1\text{-C}_5$ alkyl, $\text{CH}_2\text{OC}(=\text{O})\text{C}_1\text{-C}_5$ alkenyl, or $\text{CH}_2\text{OC}(=\text{O})\text{C}_1\text{-C}_5$ alkynyl (preferably $\text{C}_1\text{-C}_5$ alkyl);

R^{4d} is Me or NHMe;

R⁵ and R⁶ are each Me or combine with the carbon to which they are bonded to form a cyclopropyl ring (preferably both are Me);

R⁷ is H, Me, or Et;

T is a self-immolating group;

5 t is 0 or 1;

AA^a and each AA^b are independently selected from the group consisting of alanine, β-alanine, γ-aminobutyric acid, arginine, asparagine, aspartic acid, γ-carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;


10

p is 1, 2, 3, or 4;

q is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (preferably 2, 3, or 4);

r is 1, 2, 3, 4, or 5;


s is 0 or 1; and



15

[00122] Another preferred tubulysin analog-linker compound has a structure represented by formula (IIIc):

(IIIc)



or a pharmaceutically acceptable salt thereof;

20 wherein

R^{1c} is H, Me, or CH(Me)₂ (preferably CH(Me)₂);

R² is Me, Et, CH₂CH₂CH₃, CH(Me)₂, CH(Et)₂, or  ;

preferably CH(Me)₂, CH(Et)₂, or  ;

R³ is H, Ci-C₅ alkyl, Ci-C₅ alkenyl, Ci-C₅ alkynyl, CH₂OC(=O)Ci-C₅ alkyl, CH₂OC(=O)Ci-C₅ alkenyl, or CH₂OC(=O)Ci-C₅ alkynyl (preferably C1-5 alkyl);

5 R^{4d} is Me orNHMe;

R⁵ and R⁶ are each Me or combine with the carbon to which they are bonded to form a cyclopropyl ring (preferably both are Me);

R⁷ is H, Me, or Et;

T is a self-immolating group;

10 t is 0 or 1;

AA^a and each AA^b are independently selected from the group consisting of alanine, β-alanine, γ-aminobutyric acid, arginine, asparagine, aspartic acid, γ-carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;


15

p is 1, 2, 3, or 4;

q is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (preferably 2, 3, or 4);

r is 1, 2, 3, 4, or 5;

s is 0 or 1; and




20

[00123] Thus, R³¹ in formulae (IIia) and (IIIc) is a reactive functional group capable of reacting with a complementary functional group on the antibody.

[00124] In formulae (IIia) and (IIIc), -AA^a-[AA^b]_p- represents a polypeptide whose length is determined by the value of p (dipeptide if p is 1, tetrapeptide if p is 3, etc.). AA^a is at the carboxy terminus of the polypeptide and its carboxyl group forms a peptide (amide) bond

25


with an amine nitrogen of the tubulysin analog. Conversely, the last AA^b is at the amino terminus of the polypeptide and its α-amino group forms a peptide bond with




depending on whether *s* is 1 or 0, respectively.

- 5 [00125] In formulae (IIia) and (IIIc), preferred polypeptides -AA^a-[AA^b]_p- are Val-Cit, Val-Lys, Lys-Val-Ala, Asp-Val-Ala, Val-Ala, Lys-Val-Cit, or Asp-Val-Cit, written in the conventional N-to-C direction, as in EbN-Val-Cit-CChH). More preferably, the polypeptide is Val-Cit, Val-Lys, or Val-Ala.

- 10 [00126] As indicated by the subscript *t* equals 0 or 1, the self-immolating group is optionally present in compounds of formulae (IIia) and (IIIc). Whene present, self-immolating group C preferably is a *p*-aminobenzyl oxycarbonyl (PABC) group, whose structure is shown below, with an asterisk (*) denoting the end of the PABC bonded to an amine nitrogen of the tubulysin analog.




- 15 [00127] Examples of analog-linker compounds of this invention according to formula (IIia), wherein R⁵ and R⁶ are both methyl include compounds (IIIa-1) through (IIIa-4):



Compound	R ²	R ^{4d}
(IIIa-1)		
(IIIa-2)		
(IIIa-3)		
(IIIa-4)		


[00128] Specific tubulysin analog-linker compounds according to formula (IIIc) include those having structures represented by formulae (IIIc-1) through (IIIc-3):


(IIIc 1)



5

(IIIc 2)





Preparation of Conjugates

[00129] This general procedure is based on introduction of free thiol groups into an antibody by reaction of lysine ϵ -amino groups with 2-iminothiolane, followed by reaction with a maleimide-containing drug-linker moiety, such as described above. Initially the antibody is buffer exchanged into 0.1 M phosphate buffer (pH 8.0) containing 50 mM NaCl and 2 mM diethylene triamine pentaacetic acid (DTPA) and concentrated to 5-10 mg/mL. Thiolation is achieved through addition of 2-iminothiolane to the antibody. The amount of 2-iminothiolane to be added can be determined by a preliminary experiment and varies from antibody to antibody. In the preliminary experiment, a titration of increasing amounts of 2-iminothiolane is added to the antibody, and following incubation with the antibody for 1 h at RT (room temperature, circa 25 °C), the antibody is desalted into 50 mM HEPES, 5 mM Glycine, 2 mM DTPA, pH 5.5 using a SEPHADEX™ G-25 column and the number of thiol groups introduced determined rapidly by reaction with dithiodipyridine (DTDP). Reaction of thiol groups with DTDP results in liberation of thiopyridine, which can be monitored spectroscopically at 324 nm. Samples at a protein concentration of 0.5-1.0 mg/mL are typically used. The absorbance at 280 nm can be used to accurately determine the concentration of protein in the samples, and then an aliquot of each sample (0.9 mL) is incubated with 0.1 mL DTDP (5 mM stock solution in ethanol) for 10 min at RT. Blank samples of buffer alone plus DTDP are also incubated alongside. After 10 min, absorbance at 324 nm is measured and the number of thiol groups is quantitated using an extinction coefficient for thiopyridine of 19,800 M⁻¹.

[00130] Typically a thiolation level of about two to three thiol groups per antibody is desirable. For example, with some antibodies this can be achieved by adding a 15-fold molar

excess of 2-iminothiolane followed by incubation at RT for 1 h. The antibody is then incubated with 2-iminothiolane at the desired molar ratio and then desalted into conjugation buffer (50 mM HEPES, 5 mM glycine, 2 mM DTPA, pH 5.5). The thiolated material is maintained on ice while the number of thiols introduced is quantitated as described above.

5 [00131] After verification of the number of thiols introduced, the drug (cytotoxin)-linker moiety is added at a 2.5-fold molar excess per thiol. The conjugation reaction is allowed to proceed in conjugation buffer containing a final concentration of 25% propylene glycol and 5% trehalose. Commonly, the drug-linker stock solution is dissolved in 100% DMSO. The stock solution is added directly to the thiolated antibody.


10 [00132] The conjugation reaction mixture is incubated at RT for 2 h with gentle stirring. A 10-fold molar excess of N-ethyl maleimide (100 mM Stock in DMSO) is then added to the conjugation mixture and stirred for an additional hour to block any unreacted thiols.

[00133] The sample is then filtered via a 0.2 μ filter. The material is buffer exchanged via TFF VivaFlow 50 Sartorius 30 MWCO PES membrane into 10 mg/mL glycine, 20
15 mg/mL sorbitol, 15% acetonitrile pH 5.0 (5X TFF buffer exchange volume), to remove any unreacted drug. The final formulation is carried out by TFF into 20 mg/mL sorbitol, 10 mg/mL glycine, pH 5.0.


[00134] Those skilled in the art will understand that the above-described conditions and methodology are exemplary and non-limiting and that other approaches for conjugation are
20 known in the art and usable in the present invention.


[00135] A preferred antibody-drug conjugate of this invention is represented by formula (IIa):

(IIa)



wherein

R² is Me, Et, CH₂CH₂CH₃, CH(Me)₂, CH(Et)₂, or  ;

preferably CH(Me)₂, CH(Et)₂, or  ;

R³ is H, Ci-C₅ alkyl, Ci-C₅ alkenyl, Ci-C₅ alkynyl, CH₂OC(=O)Ci-C₅ alkyl, CH₂OC(=O)Ci-C₅ alkenyl, or CH₂OC(=O)Ci-C₅ alkynyl (preferably C₁₋₅ alkyl);

R^{4d} is Me orNHMe;

R⁵ and R⁶ are each Me or combine with the carbon to which they are bonded to form a cyclopropyl ring (preferably both are Me);

R⁷ is H, Me, or Et;

T is a self-immolating group;

t is 0 or 1;

AA^a and each AA^b are independently selected from the group consisting of alanine, β-alanine, γ-aminobutyric acid, arginine, asparagine, aspartic acid, γ-carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;


p is 1, 2, 3, or 4;

q is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (preferably 2, 3, or 4);

r is 1, 2, 3, 4, or 5;

s is 0 or 1;

Ab is an antibody;




where the open valence of R⁴⁰ that is bonded to Ab is denoted by an asterisk (*); and

m is 1, 2, 3, or 4.

[00136] Another preferred embodiment of an antibody-drug conjugate of this invention has a structure represented by formula (IIc):

(IIc)



wherein

R^2 is Me, Et, $\text{CH}_2\text{CH}_2\text{CH}_3$, $\text{CH}(\text{Me})_2$, $\text{CH}(\text{Et})_2$, or  ;

5

preferably $\text{CH}(\text{Me})_2$, $\text{CH}(\text{Et})_2$, or  ;

R^3 is H, $\text{C}_1\text{-C}_5$ alkyl, $\text{C}_1\text{-C}_5$ alkenyl, $\text{C}_1\text{-C}_5$ alkynyl, $\text{CH}_2\text{OC}(=\text{O})\text{C}_1\text{-C}_5$ alkyl, $\text{CH}_2\text{OC}(=\text{O})\text{C}_1\text{-C}_5$ alkenyl, or $\text{CH}_2\text{OC}(=\text{O})\text{C}_1\text{-C}_5$ alkynyl (preferably $\text{C}_1\text{-C}_5$ alkyl);

R^{4d} is Me or NHMe ;

10 R^5 and R^6 are each Me or combine with the carbon to which they are bonded to form a cyclopropyl ring (preferably both are Me);

R^7 is H, Me, or Et;

T is a self-immolating group;

t is 0 or 1;

15 AA^a and each AA^b are independently selected from the group consisting of alanine, β -alanine, γ -aminobutyric acid, arginine, asparagine, aspartic acid, γ -carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;


20 p is 1, 2, 3, or 4;

q is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (preferably 2, 3, or 4);

r is 1, 2, 3, 4, or 5;

s is 0 or 1;

Ab is an antibody;



5 where the open valence of R⁴⁰ that is bonded to Ab is denoted by an asterisk (*); and m is 1, 2, 3, or 4.

[00137] Preferred polypeptides -AA^a-[AA^b]_p- in formula (IIa) and (Iie) are the same as in formulae (IIia) and (IIIc).

[00138] Specific conjugates of tubulysin analogs of this invention include:

10 PHARMACEUTICAL COMPOSITIONS

[00139] In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound of the present invention, or of a conjugate thereof, formulated together with a pharmaceutically acceptable carrier or excipient. It may optionally contain one or more additional pharmaceutically active ingredients, such as an antibody or another drug. The pharmaceutical compositions can be administered in a combination therapy with another therapeutic agent, especially another anti-cancer agent.

[00140] The pharmaceutical composition may comprise one or more excipients.

Excipients that may be used include carriers, surface active agents, thickening or emulsifying agents, solid binders, dispersion or suspension aids, solubilizers, colorants, flavoring agents, coatings, disintegrating agents, lubricants, sweeteners, preservatives, isotonic agents, and combinations thereof. The selection and use of suitable excipients is taught in Gennaro, ed., *Remington: The Science and Practice of Pharmacy*, 20th Ed. (Lippincott Williams & Wilkins 2003), the disclosure of which is incorporated herein by reference.

[00141] Preferably, a pharmaceutical composition is suitable for intravenous, intra-muscular, subcutaneous, parenteral, spinal or epidermal administration (*e.g.*, by injection or infusion). Depending on the route of administration, the active compound may be coated in a material to protect it from the action of acids and other natural conditions that may inactivate

it. The phrase "parenteral administration" means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion. Alternatively, the pharmaceutical composition can be administered via a non-parenteral route, such as a topical, epidermal or mucosal route of administration, for example, intranasally, orally, vaginally, rectally, sublingually or topically.

[00142] Pharmaceutical compositions can be in the form of sterile aqueous solutions or dispersions. They can also be formulated in a microemulsion, liposome, or other ordered structure suitable to achieve high drug concentration. The compositions can also be provided in the form of lyophilates, for reconstitution in water prior to administration.

[00143] The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the subject being treated and the particular mode of administration and will generally be that amount of the composition which produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 0.01 per cent to about ninety-nine percent of active ingredient, preferably from about 0.1 per cent to about 70 per cent, most preferably from about 1 per cent to about 30 per cent of active ingredient in combination with a pharmaceutically acceptable carrier.

[00144] Dosage regimens are adjusted to provide a therapeutic response. For example, a single bolus may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. "Dosage unit form" refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic response, in association with the required pharmaceutical carrier.

[00145] The dosage ranges from about 0.0001 to 100 mg/kg, and more usually 0.01 to 5 mg/kg, of the host body weight. For example dosages can be 0.3 mg/kg body weight, 1 mg/kg body weight, 3 mg/kg body weight, 5 mg/kg body weight or 10 mg/kg body weight or within the range of 1-10 mg/kg. Exemplary treatment regimens are administration once per week, once every two weeks, once every three weeks, once every four weeks, once a month,

once every 3 months, or once every three to 6 months. Preferred dosage regimens include 1 mg/kg body weight or 3 mg/kg body weight via intravenous administration, using one of the following dosing schedules: (i) every four weeks for six dosages, then every three months; (ii) every three weeks; (iii) 3 mg/kg body weight once followed by 1 mg/kg body weight
5 every three weeks. In some methods, dosage is adjusted to achieve a plasma antibody concentration of about 1-1000 µg/mL and in some methods about 25-300 µg/mL.

[00146] A "therapeutically effective amount" of a compound of the invention preferably results in a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the
10 disease affliction. For example, for the treatment of tumor-bearing subjects, a "therapeutically effective amount" preferably inhibits tumor growth by at least about 20%, more preferably by at least about 40%, even more preferably by at least about 60%, and still more preferably by at least about 80% relative to untreated subjects. A therapeutically effective amount of a therapeutic compound can decrease tumor size, or otherwise ameliorate
15 symptoms in a subject, which is typically a human but can be another mammal.

[00147] The pharmaceutical composition can be a controlled or sustained release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. See, *e.g.*,
20 *Sustained and Controlled Release Drug Delivery Systems*, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.

[00148] Therapeutic compositions can be administered via medical devices such as (1) needleless hypodermic injection devices (*e.g.*, US 5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880; 4,790,824; and 4,596,556); (2) micro-infusion pumps (US 4,487,603);
25 (3) transdermal devices (US 4,486,194); (4) infusion apparatus (US 4,447,233 and 4,447,224); and (5) osmotic devices (US 4,439,196 and 4,475,196); the disclosures of which are incorporated herein by reference.

[00149] In certain embodiments, the pharmaceutical composition can be formulated to ensure proper distribution *in vivo*. For example, to ensure that the therapeutic compounds of
30 the invention cross the blood-brain barrier, they can be formulated in liposomes, which may additionally comprise targeting moieties to enhance selective transport to specific cells or organs. See, *e.g.* US 4,522,811; 5,374,548; 5,416,016; and 5,399,331; V.V. Ranade (1989) *J.*

Clin. Pharmacol. 29:685; Umezawa *et al.*, (1988) *Biochem. Biophys. Res. Commun.* 153:1038; Bloeman *et al.* (1995) *FEBS Lett.* 357:140; M. Owais *et al.* (1995) *Antimicrob. Agents Chemother.* 39:180; Briscoe *et al.* (1995) *Am. J. Physiol.* 1233:134; Schreier *et al.* (1994) *J. Biol. Chem.* 269:9090; Keinanen and Laukkanen (1994) *FEBS Lett.* 346:123; and
5 Killion and Fidler (1994) *Immunomethods* 4:273.

USES

[00150] Compounds of this invention or their conjugates can be used for treating diseases such as, but not limited to, hyperproliferative diseases, including: cancers of the head and neck which include tumors of the head, neck, nasal cavity, paranasal sinuses, nasopharynx, oral cavity, oropharynx, larynx, hypopharynx, salivary glands, and paragangliomas; cancers
10 of the liver and biliary tree, particularly hepatocellular carcinoma; intestinal cancers, particularly colorectal cancer; ovarian cancer; small cell and non-small cell lung cancer (SCLC and NSCLC); breast cancer sarcomas, such as fibrosarcoma, malignant fibrous histiocytoma, embryonal rhabdomyosarcoma, leiomyosarcoma, neurofibrosarcoma, osteosarcoma, synovial sarcoma, liposarcoma, and alveolar soft part sarcoma; leukemias such as acute promyelocytic leukemia (APL), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myelogenous leukemia (CML); neoplasms of the central nervous systems, particularly brain cancer; multiple myeloma (MM), lymphomas such as Hodgkin's lymphoma, lymphoplasmacytoid lymphoma, follicular lymphoma, mucosa-associated
15 lymphoid tissue lymphoma, mantle cell lymphoma, B-lineage large cell lymphoma, Burkitt's lymphoma, and T-cell anaplastic large cell lymphoma. Clinically, practice of the methods and use of compositions described herein will result in a reduction in the size or number of the cancerous growth and/ or a reduction in associated symptoms (where applicable). Pathologically, practice of the method and use of compositions described herein will produce a
20 pathologically relevant response, such as: inhibition of cancer cell proliferation, reduction in the size of the cancer or tumor, prevention of further metastasis, and inhibition of tumor angiogenesis. The method of treating such diseases comprises administering a therapeutically effective amount of an inventive combination to a subject. The method may be repeated as necessary. Especially, the cancer can be renal, lung, gastric, or ovarian cancer.



30 **[00151]** Compounds of this invention or their conjugates can be administered in combination with other therapeutic agents, including antibodies, alkylating agents, angiogenesis inhibitors, antimetabolites, DNA cleavers, DNA crosslinkers, DNA

intercalators, DNA minor groove binders, enediynes, heat shock protein 90 inhibitors, histone deacetylase inhibitors, immunomodulators, microtubule stabilizers, nucleoside (purine or pyrimidine) analogs, nuclear export inhibitors, proteasome inhibitors, topoisomerase (I or II) inhibitors, tyrosine kinase inhibitors, and serine/threonine kinase inhibitors. Specific therapeutic agents include adalimumab, ansamitocin P3, auristatin, bendamustine, bevacizumab, bicalutamide, bleomycin, bortezomib, busulfan, callistatin A, camptothecin, capecitabine, carboplatin, carmustine, cetuximab, cisplatin, cladribin, cytarabin, cryptophycins, dacarbazine, dasatinib, daunorubicin, docetaxel, doxorubicin, duocarmycin, dynemycin A, epothilones, etoposide, floxuridine, fludarabine, 5-fluorouracil, gefitinib, gemcitabine, ipilimumab, hydroxyurea, imatinib, infliximab, interferons, interleukins, β -lapachone, lenalidomide, irinotecan, maytansine, mechlorethamine, melphalan, 6-mercaptopurine, methotrexate, mitomycin C, nilotinib, oxaliplatin, paclitaxel, procarbazine, suberoylanilide hydroxamic acid (SAHA), 6-thioguanidine, thiotepa, teniposide, topotecan, trastuzumab, trichostatin A, vinblastine, vincristine, and vindesine.

15 EXAMPLES

[00152] The practice of this invention can be further understood by reference to the following examples, which are provided by way of illustration and not of limitation.

Example 1 - Compounds (Ia-2) and (Ia-6)



[00153] The synthesis of compounds (Ia-2) and (Ia-6) is shown in the scheme of Fig. 1.

[00154] To a solution of (5)-2-((tert-butoxycarbonyl)amino)-3-(4-nitrophenyl)propanoic acid **1** (2.0 g, 6.45 mmol; Cong *et al.* 2014) in dichloromethane (DCM) (20 mL) at 0 °C was

added 4-(dimethylamino)pyridine (DMAP, 1.18 g, 9.67 mmol) and then 2,2-dimethyl-1,3-dioxane-4,6-dione **2** (Meldrum's acid, 1.02 g, 7.09 mmol). Solid *N*-(3-dimethylaminopropyl)-*N*'-ethylcarbodiimide hydrochloride (EDC, 1.36 g, 7.09 mmol) was added. The reaction was stirred at 0 °C for 8 h. The brown reaction mixture was washed with 5% aqueous KHSO₄ solution (4x) and brine. The organic layer was dried over anhydrous MgSO₄ and filtered to give crude (5)-tert-butyl (1-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)-1-hydroxy-3-(4-nitrophenyl)propan-2-yl)carbamate **3** as a yellow DCM solution which was used directly in the next step. MS (ESI⁺) *m/z* 437.4 (M + H)⁺.

[00155] To a solution of the above compound **3** in DCM (50 mL) at 0 °C was added acetic acid (4.06 mL, 71.0 mmol) followed by NaBH₄ (0.610 g, 16.1 mmol) in 0.2 gram portions over 15 min. After stirring at 0 °C for 2 h, additional NaBH₄ (0.2 g) was added. After stirring at 0 °C for an additional 30 min, the reaction was complete. The reaction was quenched with brine and extracted with DCM (3x). The pooled organic extracts were dried over anhydrous MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel flash chromatography (gradient from 0% to 40% EtOAc/DCM) to afford (R)-tert-butyl (1-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)-3-(4-nitrophenyl)propan-2-yl)carbamate **4** (2.54 g, 93%) as a clear tan oil. ¹H NMR (CDCl₃) δ 8.20 (d, *J* = 8.8 Hz, 2H), 7.42 (d, *J* = 8.8 Hz, 2H), 4.31 (m, 1H), 3.86 (br s, 1H), 3.64 (s, 1H), 2.93 - 3.03 (m, 2H), 2.16 - 2.38 (m, 2H), 1.80 (s, 3H), 1.78 (s, 3H), 1.37 (s, 9H). MS (ESI⁺) *m/z* 423.4 (M + H)⁺.

[00156] A solution of compound **4** (2.54 g, 6.01 mmol) in toluene (50 mL) was stirred at 90 °C for 6 h. After cooling to room temperature (RT), the reaction mixture was concentrated *in vacuo*. The residue was purified by silica gel flash chromatography (gradient from 0% to 60% EtOAc/DCM) to afford (R)-tert-butyl 2-(4-nitrobenzyl)-5-oxopyrrolidine-1-carboxylate **5** (0.80 g, 42%) as a tan solid. ¹H NMR (CDCl₃) δ ppm 8.22 (d, *J* = 8.6 Hz, 2H), 7.41 (d, *J* = 8.6 Hz, 2H), 4.39 - 4.48 (m, 1H), 3.31 (dd, *J* = 13.2, 3.6 Hz, 1H), 2.87 (dd, *J* = 13.2, 9.2 Hz, 1H), 2.39 - 2.48 (m, 1H), 1.98 - 2.12 (m, 1H), 1.73 - 1.84 (m, 2H), 1.60 (s, 9 H). MS (ESI⁺) *m/z* 343.2 (M + Na)⁺.

[00157] To a solution of compound **5** (150 mg, 0.468 mmol) in tetrahydrofuran (THF, 3 mL) at -78 °C was added LiHMDS (1.17 mL, 1.17 mmol, 1M in toluene). The reaction mixture was stirred at -78 °C for 30 min. Iodomethane (266 mg, 1.87 mmol) in 1 mL of THF was added dropwise. The reaction mixture was stirred at -78 °C for 2 h, gradually warmed up to 0 °C, and then stirred at 0 °C for 1 h. The reaction was quenched by adding saturated

aqueous NH_4Cl solution and extracted with DCM (3x). The combined organic extracts were dried over anhydrous MgSO_4 , filtered, and concentrated *in vacuo*. The residue was purified on a C18 Phenomenex Luna S5 ODS 30 x 100 mm reverse phase preparative HPLC column eluting with 10-90% aq. CH_3CN containing 0.05% trifluoroacetic acid (TFA) over a 12
5 minute gradient to afford (S)-tert-butyl 3,3-dimethyl-5-(4-nitrobenzyl)-2-oxopyrrolidine-1-carboxylate **6** (61 mg, 37%) as a white solid. $^1\text{H NMR}$ (CDCl_3) δ 8.18 (d, $J = 8.6$ Hz, 2H), 7.38 (d, $J = 8.6$ Hz, 2H), 4.19 - 4.28 (m, 1H), 3.59 (dd, $J = 13.0, 3.5$ Hz, 1H), 2.75 (dd, $J = 13.0, 9.9$ Hz, 1H), 1.83 (dd, $J = 13.0, 8.3$ Hz, 1H), 1.61 (m, 1H), 1.59 (s, 9H), 1.23 (s, 3H), 1.15 (s, 3H). MS (ESI⁺) m/z 719.1 (2M + Na)⁺.

10 **[00158]** To a solution of compound **6** (110 mg, 0.316 mmol) in THF (1.0 mL) and MeOH (1.0 mL) at RT was added 3N aqueous NaOH solution (0.21 mL, 0.63 mmol) dropwise. The reaction mixture was stirred at RT for 4 h. After cooling to 0 °C, the pH of the reaction mixture was adjusted to pH 3 with 1N aqueous HCl solution and extracted with DCM (3x). The combined organic extracts were dried over anhydrous MgSO_4 , filtered, and concentrated
15 *in vacuo* to give crude (S)-4-((tert-butoxycarbonyl)amino)-2,2-dimethyl-5-(4-nitrophenyl)pentanoic acid **7**. MS (ESI⁺) m/z 755.0 (2M + Na)⁺.

[00159] The above crude product was dissolved in 1.5 mL of DCM. TFA (0.5 mL) was added. The reaction mixture was stirred at RT for 1 h and then concentrated *in vacuo*. The residue was purified on a C18 Phenomenex Luna S5 ODS 30 x 100 mm reverse phase
20 preparative HPLC column eluting with 10-90% aq CH_3CN containing 0.05% TFA over a 12 minute gradient to give (S)-4-amino-2,2-dimethyl-5-(4-nitrophenyl)pentanoic acid **8** (48 mg, 40%) as a white solid. $^1\text{H NMR}$ (CD_3OD) δ 8.25 (d, $J = 8.8$ Hz, 2H), 7.55 (d, $J = 8.8$ Hz, 2H), 3.58 - 3.66 (m, 1H), 3.03 - 3.11 (m, 2H), 1.97 (dd, $J = 15.4, 6.6$ Hz, 1H), 1.75 (dd, $J = 15.4, 3.7$ Hz, 1H), 1.23 (s, 3H), 1.10 (s, 3H). MS (ESI⁺) m/z 296.3 (M + Na)⁺.

25 **[00160]** To a solution of 2-((5*R*,1*R*)-10-((5)-sec-butyl)-7-isopropyl-2-((*R*)-1-methylpiperidin-2-yl)-3,9,12-trioxo-8-propyl-4-oxa-2,8,11-triazadodecan-5-yl)thiazole-4-carboxylic acid **9** (Cong *et al.* 2014, 20 mg, 0.034 mmol) in DMF (0.5 mL) was added *N,N,N',N'*-tetramethyl-*O*-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (HATU, 15.7 mg, 0.041 mmol) and *N,N*-diisopropylethylamine (DIEA, 0.018 mL, 0.103 mmol). The
30 reaction mixture was stirred at RT for 30 min. A solution of pentanoic acid **8** (9.15 mg, 0.034 mmol) and 1 eq. of DIEA (4.4 mg, 0.034 mmol) in DMF (0.5 mL) were added and the reaction mixture was stirred at RT overnight. The reaction mixture was purified on a C18



Phenomenex Luna S5 ODS 30 x 100 mm reverse phase HPLC column eluting with 10-90% aq CH₃CN containing 0.05% TFA over a 12 minute gradient to give (S)-5-(4-nitrophenyl)-4-(2-((5R,7R,10S)-10-((S)-sec-butyl)-7-isopropyl-12-((R)-1-methylpiperidin-2-yl)-3,9,12-trioxo-8-propyl-4-oxa-2,8, 11-triazadodecan-5-yl)thiazole-4-carboxamido)-2,2-

5 dimethylpentanoic acid (**Ia-6**) (16 mg, 56%) as a white solid. MS (ESI⁺) m/z 830.2 (M + H)⁺.


[00161] To a solution of the compound (**Ia-6**) (15 mg, 0.018 mmol) in MeOH (4 mL) was added palladium on carbon, 50%> wet (7.69 mg, 3.61 μmol). The resulting suspension was stirred under a hydrogenballoon at RT for 4 h. The reaction mixture was filtered through a pipette containing a cotton plug and CELITE™ and the filtrate was concentrated *in vacuo*.

10 The residue was purified on a CI8 Phenomenex Luna S5 ODS 21 x 100 mm reverse phase preparative HPLC column eluting with 10-90% aq CH₃CN containing 0.05% TFA over a 12 minute gradient to give (S)-5-(4-aminophenyl)-4-(2-((5R,7R,10S)-10-((S)-sec-butyl)-7-isopropyl-12-((R)-1-methylpiperidin-2-yl)-3,9,12-trioxo-8-propyl-4-oxa-2,8,1 1-triazadodecan-5-yl)thiazole-4-carboxamido)-2,2-dimethylpentanoic acid (**Ia-2**) (6 mg, 37%)
 15 as a white solid. ¹H NMR (CD₃OD) δ 8.03 (s, 1H), 7.35 (d, *J* = 8.1 Hz, 2H), 7.16 (d, *J* = 8.1 Hz, 2H), 5.62 (d, *J* = 10.8 Hz, 1H), 4.64 - 4.74 (m, 1H), 4.44 (br s, 1H), 3.78 (m, 1H), 3.41 - 3.53 (m, 2H), 3.01 - 3.12 (m, 2H), 2.83 - 2.96 (m, 1H), 2.75 (s, 3H), 2.72 (s, 3H), 2.22 (m, 5H), 1.95 (m, 3H), 1.68 - 1.85 (m, 3H), 1.23 (s, 3H), 1.20 (d, *J* = 7.04 Hz, 6H), 1.16 (s, 3H), 0.98-1.08 (m, 16H). MS (ESI⁺) m/z 800.1 (M + H)⁺.

20 *Example 2 - Compounds (Ia-1) and (Ia-5)*




[00162] Generally following the procedure of Fig. 1 and Example 1, acid **10** (Cheng *et al.* 2013) was used to prepare compound (**Ia-5**), which was then converted to compound (**Ia-1**) (10 mg, 44% over two steps).




5 [00163] The analytical properties of compound (**Ia-1**) were: ^1H NMR (400MHz, CD_3OD) δ 8.04 (s, 1H), 7.38 (d, $J = 8.4$ Hz, 2H), 7.18 (d, $J = 8.4$ Hz, 2H), 5.70 (d, $J = 10.6$ Hz, 1H), 4.55 (d, $J = 8.2$ Hz, 1H), 4.45-4.43 (m, 1H), 3.79 (d, $J = 9.5$ Hz, 1H), 3.57-3.53 (m, 1H), 3.47-3.45 (m, 1H), 3.26 - 3.14 (m, 1H), 3.06 (m, 1H), 2.93 - 2.81 (m, 3H), 2.74 (s, 3H), 2.39 - 2.33 (m, 1H), 2.22 - 2.25 (m, 4H), 2.18 (s, 3H), 1.93 - 1.91 (m, 3H), 1.82 - 1.69 (m, 4H),
10 1.67 - 1.58 (m, 3H), 1.19 (s, 3H), 1.14 (s, 3H), 1.05 - 0.86 (m, 17H); MS (ESI $^+$) m/z 785.5 ($\text{M} + \text{H}$) $^+$.

[00164] The analytical properties of compound (**Ia-5**) were: ^1H NMR (400MHz, CD_3OD) δ 8.17 (d, $J = 8.4$ Hz, 2H), 8.04 (s, 1H), 7.48 (d, $J = 8.4$ Hz, 2H), 5.75 (d, $J=12.1$ Hz, 1H), 4.64 (t, $J = 8.9$ Hz, 1H), 4.58 - 4.47 (m, 1H), 3.75 (dd, $J = 12.2, 2.8$ Hz, 1H), 3.59 (m, 1H),
15 3.44 (d, $J = 12.2$ Hz, 1H), 3.20 - 3.09 (m, 1H), 3.07 - 2.96 (m, 3H), 2.74 (s, 3H), 2.41 - 2.31 (m, 1H), 2.22 - 2.24 (m, 3H), 2.19 (s, 3H), 1.93 (m, 4H), 1.79 (m, 3H), 1.66 - 1.50 (m, 2H), 1.21 (s, 3H), 1.15 (s, 3H), 1.05 (d, $J = 6.6$ Hz, 3H), 1.00 - 0.86 (m, 17H); MS (ESI $^+$) m/z 815.4 ($\text{M} + \text{H}$) $^+$.

Example 3 - Compounds (Ia-3) and (Ia-7)



20



[00165] Fig. 2 shows a scheme for the synthesis of acid **19**, which is a precursor for the synthesis of compounds (**1a-7**) and (**1a-3**).

[00166] Dicyclohexylcarbodiimide (DCC, 0.824 g, 3.99 mmol) was added to a mixture of methyl 2-((1R,3R)-1-hydroxy-4-methyl-3-(propylamino)pentyl)thiazole-4-carboxylate **11** (Cheng *et al.* 2013, 1 g, 3.33 mmol), Boc-protected valine **12** (0.796 g, 3.66 mmol) and *t*-butanol hydrate (0.612 g, 3.99 mmol) in DCM (15 mL) at 0 °C. The reaction mixture was allowed to warm up to RT and stirred at RT overnight. The solid was filtered off, and the filtrate was concentrated. The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-8% MeOH in DCM containing 1% NH₄OH to afford 1.3 g of methyl 2-((6S,9R,11R)-6,11-diisopropyl-2,2-dimethyl-4,7-dioxo-3,8-dioxo-5,12-diazapentadecan-9-yl)thiazole-4-carboxylate **13** as a colorless oil. MS: (+) *m/z* 500.3 (M+1).

[00167] A solution of compound **13** (0.5 g, 1.001 mmol) in *o*-xylene (3 mL) was heated at 120 °C overnight. The solvent was evaporated off. The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-100% EtOAc in hexanes to afford 0.29 g of methyl 2-((1R,3R)-3-((S)-2-((tert-butoxycarbonyl)amino)-3-methyl-N-propylbutanamido)-1-hydroxy-4-methylpentyl)thiazole-4-carboxylate **14** as a light-yellow solid. MS: (+) *m/z* 500.3 (M+1).

[00168] TFA (7.7 mL, 1.571 mmol) was added to a mixture of compound **14** (0.785 g, 1.571 mmol) in DCM (15 mL). After the reaction mixture was stirred at RT for 30 min, it was concentrated by evaporation of solvent, diluted with EtOAc, and washed once with saturated aqueous NaHCO₃. The aqueous solution was back-extracted twice with EtOAc. The combined organic layers were dried, filtered, and concentrated to afford 0.63 g of methyl 2-((1R,3R)-3-((S)-2-amino-3-methyl-N-propylbutanamido)-1-hydroxy-4-methylpentyl)thiazole-4-carboxylate **15** as a light-yellow solid. MS: (+) *m/z* 400.3 (M+1).

[00169] DCC (0.258 g, 1.251 mmol) was added to a mixture of compound **15** (0.25 g, 0.626 mmol), (i?)-1-methylpiperidine-2-carboxylic acid **16** (0.11 g, 0.751 mmol, Oakwood

Products), and *t*-butanol hydrate (0.192 g, 1.251 mmol) in DCM (10 mL) at 0 °C. The reaction mixture was allowed to warm to RT and stirred at RT overnight. The solid was filtered off, and the filtrate was concentrated. The residue was dissolved in EtOAc, and washed once with saturated aqueous NaHCO₃. The aqueous solution was back-extracted
5 twice with EtOAc. The combined organic layers were dried, filtered, and concentrated. The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-20% MeOH in DCM to afford 0.12 g of methyl 2-((1R,3R)-1-hydroxy-4-methyl-3-((S)-3-methyl-2-((R)-1-methylpiperidine-2-carboxamido)-N-propylbutanamido)pentyl)thiazole-4-carboxylate **17** as a light yellow solid. MS: (+) m/z 525.3 (M+).

10 **[00170]** LiOH (10.95 mg, 0.457 mmol) in water (0.5 mL) was added to a solution of compound **17** (0.12 g, 0.229 mmol) in THF (1 mL) at RT. After the reaction mixture was stirred at RT for 2 h. The solvent was removed by evaporation. The crude product was purified by flash chromatography, eluting from silica gel with a gradient of 0-30% MeOH in DCM to afford 95 mg of 2-((1R,3R)-1-hydroxy-4-methyl-3-((S)-3-methyl-2-((R)-1-
15 methylpiperidine-2-carboxamido)-N-propylbutanamido)pentyl)thiazole-4-carboxylic acid **18** as a white solid. MS: (+) m/z 511.3 (M+).





[00171] A solution of compound **18** (95 mg, 0.186 mmol) in pyridine (1.8 mL) was cooled in an ice-water bath and acetic anhydride (0.088 mL, 0.930 mmol) was added. The reaction mixture was allowed to warm up to RT, and stirred at RT overnight. A 1:1 (v/v) solution of
20 degassed water and THF (8 mL) was added after the reaction mixture was cooled in an ice-water bath. The reaction mixture was then stirred at RT for 8 h. The solvent was evaporated off. The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-30% MeOH in DCM to afford 90 mg of 2-((1R,3R)-1-acetoxy-4-methyl-3-((S)-3-methyl-2-((R)-1-methylpiperidine-2-carboxamido)-N-propylbutanamido)pentyl)thiazole-4-
25 carboxylic acid **19** as a white solid. MS: (+) m/z 553.3 (M+).

[00172] Generally following the procedure of **Fig. 1** and Example 1, acid **19** was used to prepare compound (**Ia-7**), which was then converted to compound (**Ia-3**) (11 mg, 48% over two steps). The analytical properties of compound (**Ia-3**) were: ¹H NMR (400MHz, CD₃OD) δ 8.03 (s, 1H), 7.92 (d, *J* = 9.5 Hz, 1H), 7.31 (d, *J* = 8.4 Hz, 2H), 7.11 (d, *J* = 8.4 Hz, 2H),
30 5.75 (d, *J* = 10.8 Hz, 1H), 4.59 (d, *J* = 7.9 Hz, 1H), 4.45 - 4.43 (m, 1H), 3.79 (d, *J* = 9.5 Hz, 1H), 3.57 - 3.53 (m, 1H), 3.47 - 3.45 (m, 1H), 3.26 - 3.14 (m, 1H), 3.06 (m, 1H), 2.93 - 2.81 (m, 3H), 2.74 (s, 3H), 2.39 - 2.33 (m, 1H), 2.22 - 2.25 (m, 4H), 2.18 (s, 3H), 1.93 - 1.91 (m,

3H), 1.82 - 1.69 (m, 4H), 1.67 - 1.58 (m, 1H), 1.20 (s, 3H), 1.16 (s, 3H), 1.08 - 0.96 (m, 14H), 0.91 (d, $J = 6.6$ Hz, 3H); MS (ESI⁺) m/z 771.3 (M + H)⁺.

[00173] The analytical properties of compound (**Ia-7**) were: ¹H NMR (400MHz, CD₃OD) δ 8.13 (d, $J = 8.6$ Hz, 2H), 8.04 (s, 1H), 7.48 (d, $J = 8.6$ Hz, 2H), 5.75 (d, $J = 11.8$ Hz, 1H), 4.64 - 4.7 (m, 2H), 3.77 (d, $J = 9.7$ Hz, 1H), 3.60 - 3.39 (m, 2H), 3.23 - 3.12 (m, 2H), 3.07 - 2.96 (m, 3H), 2.74 (s, 3H), 2.36 (t, $J = 11.8$ Hz, 1H), 2.22 - 2.24 (m, 3H), 2.18 (s, 3H), 1.93 (m, 3H), 1.79 (m, 3H), 1.83 - 1.74 (m, 2H), 1.23 (s, 3H), 1.19 (s, 3H), 1.11 - 0.87 (m, 17H); MS (ESI⁺) m/z 801.4 (M + H)⁺.

Example 4 - Compounds (**Ib-1**) to (**Ib-4**)



[00174] The synthesis of compounds (**Ib-1**) to (**Ib-4**) is shown in the scheme of **Fig. 3**.

[00175] To a solution of (7?)-tert-butyl 2-(4-nitrobenzyl)-5-oxopyrrolidine-1-carboxylate **5** (740 mg, 2.31 mmol) in THF (15 mL) at -78 °C was added LiHMDS (2.31 mL, 2.31 mmol, IN toluene) dropwise. The brown solution was stirred at -78 °C for 30 min. A solution of 3-iodoprop-1-ene **20** (388 mg, 2.31 mmol) in 2 mL of THF was added dropwise. The reaction mixture was stirred at -78 °C for 7 h. The reaction was quenched by adding saturated aq. NaHCCb solution. After warming up to RT, the mixture was extracted with EtOAc (3x). The combined organic extracts were washed with brine, dried over anhydrous MgSO₄, filtered, and concentrated *in vacuo* to give a thick oil which was purified by silica gel flash chromatography (gradient from 0% to 50% EtOAc/hexanes) to afford (3S,5R)-tert-butyl 3-allyl-5-(4-nitrobenzyl)-2-oxopyrrolidine-1-carboxylate **21** (0.60 g, 72%) as a tan solid. ¹H NMR (CDCl₃) δ 8.22 (d, *J* = 8.8 Hz, 2H), 7.41 (d, *J* = 8.8 Hz, 2H), 5.74 (ddt, *J* = 17.2, 9.9, 7.0, 7.0 Hz, 1H), 5.03 - 5.12 (m, 2H), 4.36 (td, *J* = 8.6, 3.5 Hz, 1H), 3.29 (dd, *J* = 13.2, 3.5 Hz, 1H), 2.84 (dd, *J* = 13.2, 9.5 Hz, 1H), 2.49 - 2.68 (m, 2H), 2.10 - 2.21 (m, 1H), 1.92 (dd, *J* = 13.2, 8.6 Hz, 1H), 1.74 (td, *J* = 12.4, 8.6 Hz, 1H), 1.60 (s, 9H). MS (ESI⁺) *m/z* 743.5 (2M + Na)⁺.

[00176] A solution of compound **21** (330 mg, 0.92 mmol) in DCM (6 mL) at -78 °C was bubbled with an O₃ stream until a blue color appeared (~3 min). The reaction mixture was flushed with O₂ for 5 min, and then N₂ for 5 min. DMSO (0.34 mL, 4.58 mmol) was added and the reaction mixture was warmed to RT and stirred at RT overnight. The reaction mixture was washed with water and brine. The organic layer was dried over anhydrous MgSO₄, filtered, and concentrated *in vacuo* to give a thick oil which was purified by silica gel flash chromatography (gradient from 0% to 70% EtOAc/DCM) to afford (3R,5R)-tert-butyl 5-(4-nitrobenzyl)-2-oxo-3-(2-oxoethyl)pyrrolidine-1-carboxylate **22** (0.26 g, 78%) as colorless oil. ¹H NMR (CDCl₃) δ 9.76 (s, 1H), 8.16 (d, *J* = 8.8 Hz, 2H), 7.40 (d, *J* = 8.8 Hz, 2H), 4.35 (td, *J* = 8.8, 3.6 Hz, 1H), 3.25 (dd, *J* = 13.2, 3.6 Hz, 1H), 3.05 (dd, *J* = 18.8, 4.2 Hz, 1H), 2.85 - 2.97 (m, 2H), 2.52 (dd, *J* = 18.8, 8.2 Hz, 1H), 2.07 - 2.15 (m, 1H), 1.66 (td, *J* = 12.5, 8.5 Hz, 1H), 1.54 (s, 9H). MS (ESI⁺) *m/z* 747.5 (2M + Na)⁺.

[00177] To a solution of compound **22** (259 mg, 0.72 mmol) in MeOH (5 mL) at 0 °C was added NaBH₄ (27.0 mg, 0.715 mmol). The reaction mixture was stirred at 0 °C for 20 h. The reaction was quenched by adding 10% aqueous citric acid and extracted with EtOAc (3x). The combined organic extracts were dried over anhydrous MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel flash chromatography (gradient from 0% to 80% EtOAc/DCM) to afford (3R,5R)-tert-butyl 3-(2-hydroxyethyl)-5-(4-nitrobenzyl)-2-

oxopyrrolidine-1-carboxylate **23** (0.16 g, 60%) as a colorless oil. ¹H NMR (CDCl₃) δ 8.15 (d, *J* = 8.6 Hz, 2H), 7.39 (d, *J* = 8.6 Hz, 2H), 4.33 (td, *J* = 8.8, 3.6 Hz, 1H), 3.71 - 3.80 (m, 1H), 3.58 - 3.68 (m, 1H), 3.25 (dd, *J* = 13.2, 3.6 Hz, 1H), 2.90 (br s, 1H), 2.83 (dd, *J* = 13.2, 9.4 Hz, 1H), 2.64 - 2.74 (m, 1H), 1.95 - 2.06 (m, 2H), 1.68 - 1.79 (m, 1H), 1.59 (m, 1H), 1.54 (s, 9H). MS (ESI⁺) *m/z* 751.5 (2M + Na)⁺.

[00178] To a solution of compound **23** (156 mg, 0.43 mmol) in THF (4 mL) at RT was added mesyl chloride (0.043 mL, 0.58 mmol) and DIEA (0.097 mL, 0.56 mmol). The reaction mixture was stirred at RT for 3 h. The reaction mixture was diluted with DCM and washed with water. The organic layer was dried over anhydrous MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified by silica gel flash chromatography (gradient from 0% to 60% EtOAc/DCM) to afford (3R,5R)-tert-butyl 3-(2-((methylsulfonyl)oxy)-ethyl)-5-(4-nitrobenzyl)-2-oxopyrrolidine-1-carboxylate **24** (0.17 g, 91%) as colorless oil. ¹H NMR (CDCl₃) δ 8.20 (d, *J* = 8.6 Hz, 2H), 7.42 (d, *J* = 8.6 Hz, 2H), 4.29 - 4.45 (m, 2H), 3.26 (dd, *J* = 13.0, 3.4 Hz, 1H), 3.02 (s, 3H), 2.88 (dd, *J* = 13.2, 9.4 Hz, 1H), 2.59 - 2.69 (m, 1H), 2.30 (ddt, *J* = 14.7, 7.0, 5.4, 5.4 Hz, 1H), 2.13 (dd, *J* = 13.0, 8.3 Hz, 1H), 1.67 - 1.81 (m, 3H), 1.58 (s, 9H). MS (ESI⁺) *m/z* 907.5 (2M + Na)⁺.

[00179] To a solution of compound **24** (80 mg, 0.18 mmol) in DMF (1.0 mL) at 0 °C was added NaH (14.5 mg, 0.36 mmol). The reaction mixture was stirred at 0 °C for 1 h and RT for 2 h. To the reaction mixture was added THF, MeOH (0.5 mL each), and 3 eq. IN aqueous NaOH solution. The reaction mixture was stirred at RT for 3 h. After cooling to 0 °C, the pH of the reaction mixture was adjusted to pH 3-4 with IN aq. HCl and then extracted with DCM (3x). The combined organic extracts were dried over anhydrous MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified on a C18 Phenomenex Luna S5 ODS 30 x 100 mm reverse phase preparative HPLC column eluting with 10-90% aq CH₃CN containing 0.05% TFA over a 12 minute gradient). The following two compounds were isolated:

- (*S*)-1-(2-((tert-butoxycarbonyl)amino)-3-(4-nitrophenyl)propyl)cyclopropane-carboxylic acid **25** (20 mg, 30%). ¹H NMR (CDCl₃) δ 8.15 (d, *J* = 8.6 Hz, 2H), 7.37 (d, *J* = 8.6 Hz, 2H), 4.11 (m, 1H), 2.79 - 3.03 (m, 2H), 1.38 (s, 9H), 1.30 (m, 2H), 0.86 (m, 2H), 0.76 (m, 2H). MS (ESI⁺) *m/z* 751.6 (2M + Na)⁺.
- (*s*)-Methyl 1-(2-((tert-butoxycarbonyl)amino)-3-(4-nitrophenyl)propyl)cyclopropanecarboxylate **26** (20 mg, 29%). ¹H NMR (CDCl₃) δ 8.15 (d, *J* = 8.2 Hz, 2H),

7.36 (d, $J = 8.2$ Hz, 2H), 4.05 (m, 1H), 2.80 - 3.02 (m, 2H), 1.82 - 1.93 (m, 2H), 1.38 (s, 9H), 0.74 - 0.82 (m, 2H), 0.62 - 0.71 (m, 2H). MS (ESI⁺) m/z 379.1 (M + H)⁺.

[00180] To a solution of cyclopropanecarboxylic acid **25** (20 mg, 0.055 mmol) in DCM (0.75 mL) was added TFA (0.25 mL). The reaction mixture was stirred at RT for 2 h and concentrated *in vacuo*. The product (S)-1-(2-amino-3-(4-nitrophenyl)propyl)cyclopropanecarboxylic acid **27** was obtained as its TFA salt and was used directly in the next reaction without purification (21 mg, 100%). ¹H NMR (CD₃OD) δ 8.24 (d, $J = 8.8$ Hz, 2H), 7.54 (d, $J = 8.80$ Hz, 2H), 3.85 - 3.95 (m, 1H), 3.08 (dd, $J = 7.2, 2.2$ Hz, 2H), 1.98 - 2.08 (m, 1H), 1.64 (dd, $J = 15.4, 4.2$ Hz, 1H), 1.34 - 1.43 (m, 1H), 1.23 - 1.30 (m, 1H), 0.79 - 0.87 (m, 1H), 0.66 (m, 1H). MS (ESI⁺) m/z 265.2 (M + H)⁺.

[00181] Acid **27** was coupled with compound **9** to yield 1-((S)-2-(2-((5R,7R,10S)-10-((S)-sec-butyl)-7-isopropyl-12-((R)-1-methylpiperidin-2-yl)-3,9,12-trioxo-8-propyl-4-oxa-2,8,1-triazadodecan-5-yl)thiazole-4-carboxamido)-3-(4-nitrophenyl)propyl)cyclopropanecarboxylic acid (**Ib-3**), generally following the procedures described hereinabove. Then, compound (**Ib-3**) was converted to 1-((S)-3-(4-aminophenyl)-2-(2-((5R,7R,10S)-10-((S)-sec-butyl)-7-isopropyl-12-((R)-1-methylpiperidin-2-yl)-3,9,12-trioxo-8-propyl-4-oxa-2,8,1-triazadodecan-5-yl)thiazole-4-carboxamido)propyl)cyclopropanecarboxylic acid (**Ib-1**) by hydrogenation as described above (5 mg, 47%) as a white solid. ¹H NMR (CD₃OD) δ 8.03 (s, 1H), 7.32 (d, $J = 8.2$ Hz, 2H), 7.11 (d, $J = 8.2$ Hz, 2H), 4.60 - 4.73 (m, 2H), 3.75 (d, $J = 10.1$ Hz, 1H), 3.43 (m, 2H), 2.83 - 2.97 (m, 6H), 2.74 (s, 3H), 2.70 (s, 3H), 2.12 - 2.30 (m, 3H), 1.93 (m, 3H), 1.78 (m, 2H), 1.58 (m, 4H), 1.10 - 1.27 (m, 3H), 0.91 - 1.06 (m, 18H), 0.83 - 0.90 (m, 2H), 0.75 (m, 2H). MS (ESI⁺) m/z 798.7 (M + H)⁺.

[00182] To a solution of methyl ester **26** (20 mg, 0.053 mmol) in DCM (0.75 mL) was added TFA (0.25 mL). The reaction mixture was stirred at RT for 2h and then concentrated *in vacuo*. The product (S)-methyl 1-(2-amino-3-(4-nitrophenyl)propyl)cyclopropanecarboxylate **28** was obtained as its TFA salt and was used in the next reaction without purification (21 mg, 100%). ¹H NMR (CD₃OD) δ 8.25 (d, $J = 8.8$ Hz, 2H), 7.54 (d, $J = 8.8$ Hz, 2H), 3.87 - 3.98 (m, 1H), 3.65 (s, 3H), 3.08 (dd, $J = 7.2, 5.0$ Hz, 2H), 1.96 (dd, $J = 15.2, 8.6$ Hz, 1H), 1.75 (dd, $J = 15.2, 4.6$ Hz, 1H), 1.34 - 1.42 (m, 1H), 1.22 - 1.30 (m, 1H), 0.86 (ddd, $J = 9.4, 6.8, 4.1$ Hz, 1H), 0.73 (ddd, $J = 9.4, 6.8, 4.1$ Hz, 1H). MS (ESI⁺) m/z 279.2 (M + H)⁺.

[00183] Methyl ester **28** was coupled with compound **9** to yield methyl 1-((S)-2-(2-((5R,7R,10S)-10-((S)-sec-butyl)-7-isopropyl-12-((R)-1-methylpiperidin-2-yl)-3,9,12-trioxo-

mutandis. A sample of it (0.0555 g, 0.111 mmol) was dissolved in THF (1 mL) with DMAP (0.027 g, 0.222 mmol) and the resulting solution then treated with acetic anhydride (0.021 mL, 0.222 mmol) at RT. Pyridine (0.193 μ L, 0.222 mmol) was then added and the resulting reaction mixture then stirred at RT for 2h. The reaction mixture was quenched with 1N HCl and the solution extracted with DCM (3x). The combined organic extracts were dried with anhydrous Na₂SO₄, filtered and the filtrate concentrated *in vacuo* to afford 2-((6S,9R,11R)-6-((S)-sec-butyl)-9-isopropyl-2,2-dimethyl-4,7,13-trioxo-8-propyl-3,12-dioxo-5,8-diazatetradecan-11-yl)thiazole-4-carboxylic acid **37** (0.064 gm, 100%) as a solid. The product was used in the next step without further purification. ¹H NMR (400MHz, DMSO-d₆) δ 8.42 (s, 1H), 7.00 - 6.78 (m, 1H), 5.62 (d, *J*=11.0 Hz, 1H), 4.24 (d, *J*=7.3 Hz, 1H), 4.09 - 3.94 (m, 1H), 3.01 - 2.80 (m, 2H), 2.29 - 2.11 (m, 3H), 1.93 (br. s., 3H), 1.86 - 1.66 (m, 4H), 1.60 - 1.47 (m, 1H), 1.42 - 1.28 (m, 9H), 1.00 - 0.59 (m, 15H); MS (ESI⁺) *m/z* 542.2 (M+H)⁺.

[00187] Acid **37** (0.063 g, 0.116 mmol) and HATU (0.053 g, 0.140 mmol) were dissolved in DMF (1 mL) and the resulting solution was treated with DIEA (0.101 mL, 0.582 mmol) at RT. The reaction mixture was stirred at RT for 30 minutes. A DMF (1 mL) solution of (S)-4-amino-2,2-dimethyl-5-phenylpentanoic acid **35**, TFA salt (0.039 g, 0.116 mmol) with DIEA (0.101 mL, 0.582 mmol) was added to the activated ester and the resulting reaction mixture was stirred at RT for 1h. The reaction mixture was then purified by wet loading on a C-18 reverse phase ISCO system, eluting with 50-100% aq. CH₃CN with 0.1% TFA over a 13 minute gradient. The appropriate fractions were isolated and freeze dried to afford (S)-4-(2-((6S,9R,11R)-6-((S)-sec-butyl)-9-isopropyl-2,2-dimethyl-4,7,13-trioxo-8-propyl-3,12-dioxo-5,8-diazatetradecan-11-yl)thiazole-4-carboxamido)-2,2-dimethyl-5-phenylpentanoic acid **38** (0.053 gm, 61%) as a solid. MS (ESI⁺) *m/z* 745.4 (M+H)⁺.


[00188] Acid **38** (0.053 g, 0.071 mmol) was dissolved in DCM (1.25 mL) and the resulting solution was then treated with TFA (0.4 mL) at RT. The reaction mixture was stirred at RT for 1h then concentrated *in vacuo*. The residue was purified on a C-18 reverse phase 50 gm Gold ISCO column, eluting with 10-100% aq. CH₃CN with 0.1% TFA over a 14 minute gradient. The appropriate fractions were isolated and freeze dried to afford (S)-4-(2-((1*S*,3*S*)-1-acetoxy-3-((2*S*,3*S*)-2-amino-3-methyl-N-propylpentanamido)-4-methylpentyl)thiazole-4-carboxamido)-2,2-dimethyl-5-phenylpentanoic acid **39**, TFA salt (0.032 gm, 67%) as a white solid. ¹H NMR (400MHz, DMSO-d₆) δ 8.17 - 8.09 (m, 1H), 7.32 - 7.06 (m, 5H), 5.72 - 5.40 (m, 1H), 4.27 (d, *J*=6.6 Hz, 1H), 4.02 - 3.87 (m, 2H), 3.56

(br. s., 1H), 3.20 (d, $J=11.9$ Hz, 1H), 3.04 (t, $J=11.3$ Hz, 1H), 2.91 - 2.72 (m, 2H), 2.42 - 2.28 (m, 2H), 2.15 - 2.09 (m, 3H), 2.00 (br. s., 1H), 1.93 - 1.85 (m, 1H), 1.82 - 1.71 (m, 2H), 1.62 - 1.46 (m, 2H), 1.13 - 0.75 (m, 24H); MS (ESI⁺) m/z 645.4 (M+H)⁺.

[00189] (i?)-2-((tert-butoxycarbonyl)(methyl)amino)-3-methylbutanoic acid **40** (CAS Reg. No. 89536-85-6, 2.93 mg, 0.013 mmol) and HATU (4.81 mg, 0.013 mmol) were dissolved in DMF (0.5 mL) and the resulting solution was then treated with DIEA (7.34 μ L, 0.042 mmol) at RT. The reaction mixture was stirred at RT for 30 minutes. Acid **39**, TFA salt (0.008 g, 10.54 μ mol) dissolved in DMF (0.5 mL) along with DIEA (7.34 μ L, 0.042 mmol) was then added to the activated ester and the resulting reaction mixture was stirred at RT for 1h. The reaction mixture was purified by wet loading on an ISCO 50 gm gold reverse phase C-18 column, eluting 50-100% aq. CH₃CN with 0.1% TFA over a 13 minute gradient. The appropriate fractions were isolated and freeze dried to afford (*S*)-4-(2-((6*R*,9*S*,12*R*,14*R*)-9-((*S*)-sec-butyl)-6, 12-diisopropyl -2,2,5-trimethyl-4,7, 10,16-tetraoxo- 11-propyl-3,15-dioxo-5,8,11-triazasheptadecan-14-yl)thiazole-4-carboxamido)-2,2-dimethyl-5-phenylpentanoic acid **41** (0.009 gm, 95%) as a solid. MS (ESI⁺) m/z 858.4 (M+H)⁺.

[00190] A solution of acid **41** (0.008 g, 9.32 μ mol) in DCM (1 mL) was treated at RT with TFA (0.3 mL). The reaction mixture was stirred RT for 1 h and concentrated *in vacuo*. The residue was purified by C-18 HPLC eluting on a C18 21x100 mm column with 9.5-95% aq. CH₃CN with 0.1% TFA over a 12 minute gradient. The appropriate fractions were isolated and freeze dried to afford (*S*)-4-(2-((3*R*,6*S*,9*R*,11*R*)-6-((5)-sec-butyl)-3,9-diisopropyl-4,7,13-trioxo-8-propyl-12-oxa-2,5,8-triazatetradecan-11-yl)thiazole-4-carboxamido)-2,2-dimethyl-5-phenylpentanoic acid (**Ic-1**) (0.005 gm, 62%) as a TFA salt. ¹H NMR (400MHz, CD₃OD) δ 8.07 (s, 1H), 7.81 (d, $J=9.7$ Hz, 1H), 7.35 - 7.07 (m, 5H), 5.75 (d, $J=11.2$ Hz, 1H), 4.70 (d, $J=8.1$ Hz, 1H), 4.45 (br. s., 2H), 3.65 (d, $J=4.6$ Hz, 1H), 3.19 - 3.06 (m, 1H), 2.96 - 2.65 (m, 4H), 2.52 (s, 3H), 2.39 - 2.30 (m, 1H), 2.27 - 2.04 (m, 6H), 1.94 - 1.86 (m, 2H), 1.72 - 1.54 (m, 3H), 1.32 - 0.77 (m, 31H); MS (ESI⁺) m/z 758.4 (M+H)⁺.

Example 6 - Compound (Ic-2)



[00191] Compound (**Ic-2**) was prepared analogously to compound (**Ic-1**) using, as a precursor material, compound **60**, whose synthesis is shown schematically in **Figs. 5a-5b**.

[00192] To a solution of 2,2-diethoxyacetonitrile **44** (50g, 387 mmol) in methanol (2.0 L) was added ammonium sulfide solution(50% aq.) (52.8 mL, 387 mmol). The reaction mixture was stirred at RT overnight. The reaction mixture was concentrated *in vacuo* to remove volatiles. The brown pasty residue was dissolved in ethyl acetate and the organic solution then washed with water and brine. The organic fraction was separated and dried with anhydrous Na₂S₀₄ and filtered. The filtrate was concentrated *in vacuo* to afford a yellow solid. The solid was triturated with petroleum ether, filtered and the solid dried under high vacuum to afford 2,2-diethoxyethanethioamide **45** (35 g, 55.4%) as a white solid. ¹H NMR (CDCl₃) (400 MHz) δ 1.27 - 1.24 (two merging triplets, 3H each, J = 7.2 Hz), 3.78 - 3.61 (two merging quartets, 2H each, J = 7.2 Hz), 5.04 (s, 1H), 7.61 & 7.86 (br. peak, 2H).

[00193] A mixture of thioamide **45** (50g, 306 mmol) dissolved in methanol (450 mL) and size 3A molecular sieves (120g) was heated with stirring to 65 °C. Methyl bromopyruvate **46** (32.6 mL, 306 mmol) was added drop-wise over 15 min and the resulting reaction mixture was stirred at 65 °C for 3 h. The reaction mixture was cooled to RT and the brown solid that formed was filtered off and discarded. The filtrate was concentrated *in vacuo* to afford a black oil. The oil was dissolved in DCM and filtered through a pad of silica (60-120 mesh) and the filtrate concentrated *in vacuo*. The crude methyl 2-(diethoxymethyl)thiazole-4-carboxylate **47** (50 g, 66.5%, oil), was taken on to the next step without further purification.

[00194] A solution of ester **47** (50 g, 204 mmol) in acetone (1.5 L) was treated with 1.5 N HCl (1.0 L) drop wise at 50°C. The mixture was then heated at 60°C for 3 h. The reaction mixture was cooled to RT and the solution was and extracted with ethyl acetate (3x). The combined organic layers were separated and the organic fraction washed with saturated aq. NaCl. The organic fraction was separated and dried with anhydrous Na₂S₀₄ and filtered. The filtrate was concentrated *in vacuo*. The residue was purified by flash chromatography (230 - 400 mesh silica) with a gradient of 15 - 20% EtOAc - petroleum ether. The appropriate fractions were isolated and concentrated *in vacuo* to afford methyl 2-formylthiazole-4-carboxylate **48** (12 g., 34.4%) as a pale yellow solid. ¹H NMR (CDCl₃) (400 MHz) δ 4.02 (s, 3H), 8.54 (d, 1H, J = 1.2 Hz), 10.07 (d, 1H, J = 1.2 Hz).

[00195] A solution of 3-methylbutan-2-one **49** (50 g, 580 mmol) and titanium tetraethoxide (265 g, 1160 mmol) in anhydrous THF (750 mL) was stirred under a nitrogen atmosphere in a round bottom flask at RT. (S)-t-Butyl sulfinimide **50** (70.4g, 0.58 m) was added to the reaction mixture and the resulting reaction mixture was stirred at 70 °C
5 overnight. The reaction mixture was cooled to RT and quenched with saturated aq. NaCl (500 mL). The resulting solution was stirred for 10 min and the mixture filtered through a CELITE™ pad. The pad was washed thoroughly with ethyl acetate, and the filtrate extracted with ethyl acetate (2x). The combined organic extracts were dried with anhydrous Na₂S₀₄ and filtered. The filtrate concentrated *in vacuo*. The residue was purified by flash
10 chromatography (230 - 400 mesh silica) with a gradient of 10 - 20% EtOAc - petroleum ether mixture to afford (R,E)-2-methyl-N-(3-methylbutan-2-ylidene)propane-2-sulfinamide **51** (70 g, 63.5%) as a yellow oil. ¹H NMR (CDCb) (400 MHz) δ 1.14 - 1.11 (m, 6H), 1.23 (s, 9H), 2.31 (s, 3H), 2.57 - 2.52 (m, 1H).

[00196] A solution of DIEA (15.8 mL, 110 mmol) in anhydrous ether (200 mL) was
15 cooled to -78 °C. n-BuLi (2M, 55ml, 110 mmol) was added drop wise. The resulting mixture was warmed to 0 °C then continued to be stirred for 45 min at 0 °C. The mixture was re-cooled to -78 °C and a solution of sulfinamide **51** (10 g, 52 mmol) in ether (100 mL) was added dropwise. The reaction mixture and stirred at -78°C for 1 h. Chlorotitanium triisopropoxide (31.7 g, 121 mmol) was added and resulting reaction mixture was continue
20 stirred at -78°C for 1 h. Compound **48** (9 g, 52 mmol) was added in one portion and the resulting reaction mixture was continue stirred at -78 °C overnight. The reaction mixture was quenched with 20% acetic acid in THF and allowed to warm to RT. Water (2.5 mL) was added and the resulting solution was filtered through a pad of CELITE™. The pad was washed thoroughly with ethyl acetate. The filtrate was extracted with ethyl acetate (3x). The
25 combined organic extracts were washed 1x with saturated aq. NaCl. The organic fraction was dried with anhydrous Na₂S₀₄ and filtered. The filtrate concentrated *in vacuo*. The residue was purified by flash chromatography (230 - 400 mesh silica) with a gradient of 15 - 20% ethylacetate - petroleum ether mixture to afford methyl 2-((R,E)-3-(((R)-tert-butylsulfinyl)imino)-1-hydroxy-4-methylpentyl)thiazole-4-carboxylate **52** (9.0 g, 47%) as a
30 pale yellow viscous oil. ¹H NMR (CDCb) (400 MHz) δ 1.17 - 1.06 (m, 6H), 1.23 (s, 9H), 2.88 - 2.84 (m, 1H), 3.37 - 3.34 (m, 2H), 3.94 (s, 3H), 5.17 - 5.09 (m, 1H), 6.63 (d, 1H, J = 13.2 Hz), 8.16 - 8.13 (d, 1H, J = 13.2 Hz); MS (ESI⁺) m/z 361.0 (M+H)⁺.

[00197] A solution of compound **52** (30 g, 83 mmol) in THF (300 mL) was cooled to -78 °C. Titanium tetraethoxide (38 g, 166 mmol) was then added to the solution followed by portion-wise addition of NaBH₄ (12.6 g, 330 mmol). The mixture was stirred at -78°C for 3 h. The reaction mixture was quenched with methanol (10 mL) followed by 20% acetic acid in THF (100 mL) and allowed then allowed to warm to RT. Water (50 mL) was added and the resulting solution was filtered over a pad of CELITE™. The pad was washed thoroughly with ethyl acetate. The filtrate was extracted with ethyl acetate (3x). The combined organic extracts were washed 1x with saturated aq. NaCl and dried with anhydrous Na₂S₀₄. The filtrate was concentrated *in vacuo*. The residue was purified by flash silica gel chromatography eluting 40-50% gradient of ethylacetate in petroleum ether. The appropriate fractions were isolated and concentrated in vacuo to afford methyl 2-((1R,3R)-3-((S)-1,1-dimethylethylsulfonamido)-1-hydroxy-4-methylpentyl)thiazole-4-carboxylate **53** (20 g, 64%) as a solid. ¹H NMR (CDCl₃) (400 MHz) δ 0.90 - 0.80 (m, 6H), 1.30 (s, 9H), 1.73 - 1.68 (m, 1H), 1.94 - 1.89 (m, 1H), 2.30 - 2.23 (m, 1H), 3.47 - 3.37 (m, 2H), 3.93 (s, 3H), 5.21 - 5.18 (m, 1H), 5.58 - 5.57 (m, 1H), 8.12 (s, 1H). MS (ESI⁺) m/z 363.1 (M+H)⁺.

[00198] Compound **53** (3.15 g, 8.69 mmol) was dissolved in DCM (65 mL) along with bis(4-nitrophenyl) carbonate **53a** (CAS Reg. No. 5070-13-3, 5.29 g, 17.38 mmol). The resulting solution was then treated with triethylamine (3.03 mL, 21.72 mmol) and then the resulting reaction mixture was allowed to stir at RT overnight, turning yellow. The reaction mixture was then treated with methanamine (19.55 mL, 39.1 mmol) (2M in THF) at RT and the resulting reaction mixture was stirred at RT for 30 min. The orange slurry was filtered through a CELITE™ pad, which was washed with DCM. The filtrate was concentrated *in vacuo* and the residue purified by ISCO chromatography, eluting with 0-8.5% MeOH/DCM over a 20 min gradient. The appropriate fractions were vacuum concentrated *in vacuo*. The residue was dissolved in ethyl acetate and the solution washed 4x with 1N NaOH. The organic fraction was dried with anhydrous Na₂S₀₄, filtered and concentrated *in vacuo* to afford clean compound **54** (3.1 gm, 78%), as a solid; MS (ESI⁺) m/z 420.3 (M+H)⁺.

[00199] Methyl carboxylate **54** (3.1 g, 7.39 mmol) was dissolved in MeOH (36.9 mL) and the resulting solution was treated with 4N HCl (1.85 mL, 7.39 mmol) in dioxane at RT stirred for 1 h. The reaction mixture was then concentrated *in vacuo* to afford crude methyl 2-((1*R*,3*R*)-3-amino-4-methyl-1-((methylcarbamoyl)oxy)pentyl)thiazole-4-carboxylate **55** (2.6 g, 95%) as its solid hydrochloride salt. MS(ESI⁺) m/z 316.3 (M+H)⁺.

[00200] To a 0 °C solution of compound **55** (1.85 g, 5.85 mmol) in DCM (29.2 mL) was added 4A molecular sieves followed by propionaldehyde **56** (0.422 mL, 5.85 mmol). After stirring at 0 °C for 45 min, sodium triacetoxyborohydride (1.86 g, 8.77 mmol) was added and the reaction mixture was stirred at 0 °C for 30 min. The reaction mixture was quenched with saturated aqueous NaHCO₃ solution and allowed to warm to RT. After 20 min gas evolution ceased and the solution was then extracted 3x with DCM. The combined organic extracts were dried over anhydrous Na₂S₀₄, filtered and concentrated *in vacuo* to afford methyl 2-((li?,3i?)-4-methyl-1-((methylcarbamoyl)oxy)-3-(propylamino)pentyl)thiazole-4-carboxylate **57** (2.05 g, 93%) as a solid. MS(ESI⁺) m/z 358.5 (M+H)⁺.

[00201] Compound **57** (1.00 g, 2.80 mmol) and (2S,3S)-2-azido-3-methylpentanoic acid **58** (0.440 g, 2.80 mmol; Peltier *et al.* 2006) were stirred together in DCM (14.0 mL). Bis(2-oxooxazolidin-3-yl)phosphinic chloride (0.855 g, 3.36 mmol) was added at RT followed by DIEA (1.46 mL, 8.39 mmol). The resulting reaction mixture was then stirred at RT overnight. The reaction mixture was quenched with IN aqueous HCl solution and the mixture was extracted with DCM (3x). The combined organic extracts were then washed 3x with 10% aqueous NaHCO₃ solution. The organic fraction was dried over anhydrous Na₂S₀₄, filtered and concentrated *in vacuo*. The solid product was found to be contaminated with about 25% of an impurity that was separated in a later step, giving methyl 2-((li?,3i?)-3-((25',35)-2-azido-3-methyl-*N*-propylpentanamido)-4-methyl-1-((methylcarbamoyl)oxy)-pentyl)thiazole-4-carboxylate **59** (1.4 g, 76%) as a solid. MS(ESI⁺) m/z 497.4 (M+H)⁺.


[00202] Methyl ester **59** (1.39 g, 2.80 mmol) was dissolved in 1/1 MeOH (7.00 mL)/THF (7.00 mL) and the resulting solution was then treated at RT with 2N aqueous lithium hydroxide solution (2.80 mL, 5.60 mmol). The resulting reaction mixture was then stirred at RT for 12 h. The reaction mixture was concentrated *in vacuo* to remove any volatiles. The residue was treated with IN aqueous HCl solution and the mixture was extracted with DCM (3x). The combined organic extracts were dried over anhydrous Na₂S₀₄, filtered and concentrated *in vacuo* to afford 2-((li?,3i?)-3-((25',35)-2-azido-3-methyl-*N*-propylpentanamido)-4-methyl-1-((methylcarbamoyl)oxy)pentyl)thiazole-4-carboxylic acid **60**, still containing the impurity (1.4 g, 76%) as a solid. MS(ESI⁺) m/z 483.5 (M+H)⁺.

[00203] Coupling of pentanoic acid **35** and butanoic acid **40** to compound **60** introduce the Tup and Mep fragments, respectively, led to compound (**Ic-2**). The analytical data for compound (**Ic-2**) was as follows: ¹H NMR (400MHz, acetonitrile-d₃) δ 7.99 - 7.85 (m, 1H),

7.42 - 7.07 (m, 5H), 5.45 (d, $J=10.1$ Hz, 1H), 4.86 - 4.65 (m, 1H), 4.43 - 4.15 (m, 1H), 3.47 - 3.25 (m, 3H), 3.17 - 2.75 (m, 4H), 2.78 - 2.67 (m, 3H), 2.44 - 2.30 (m, 7H), 1.84 - 1.70 (m, 4H), 1.64 - 1.45 (m, 3H), 1.30 - 0.72 (m, 26H); MS (ESI⁺) m/z 773.3 (M+H)⁺.

Example 7- Compound (IIIa-2)

(III^a 2)



5

[00204] Fig. 6 shows schematically the preparation of compound **(IIIa-2)**.

[00205] To a solution of compound **6** (Fig. 1 and Example 6, 420 mg, 1.206 mmol) in MeOH (10 mL) under nitrogen was added Pd/C (128 mg, 0.121 mmol, Aldrich). The reaction was placed under an H₂ atmosphere (balloon) and stirred for 3.0 h. The reaction vessel was flushed with nitrogen and CELITE™ was added. The mixture was filtered
10 through a thin pad of CELITE™ and washed with MeOH. The filtrate was concentrated to give (S)-tert-butyl 5-(4-aminobenzyl)-3,3-dimethyl-2-oxopyrrolidine-1-carboxylate **61** as a light yellow solid (382 mg, 100%). ¹H NMR (400MHz, CDCl₃) δ 6.99 (d, $J = 8.3$ Hz, 1H), 6.66 (d, $J = 8.3$ Hz, 1H), 4.15 (m, 1H), 3.64 (s, 2H), 3.34 (dd, $J = 13.1, 3.4$ Hz, 1H), 2.53 (dd,
15 $J = 13.1, 10.0$ Hz, 1H), 1.86 - 1.76 (m, 1H), 1.72 - 1.64 (m, 1H), 1.61 (s, 9H), 1.22 (s, 3H), 1.16 (s, 3H); MS (ESI⁺) m/z 659.6 (2M + Na)⁺.

[00206] To a solution of compound **61** (382 mg, 1.20 mmol) and (5)-2-((5)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3 -methylbutanamido)-5 -ureidopentanoic acid **62** (CAS Reg. No. 557095-84-8, 596 mg, 1.20 mmol) in DMF (5 mL) at 0 °C were added
20 HATU (593 mg, 1.560 mmol) and 2,6-dimethylpyridine (193 mg, 1.800 mmol). The reaction mixture was stirred at RT for 1.5 h. Cold water (50 mL) was added. The solid formed was collected by filtration, washed with water, and dried under vacuum to give a tan solid that was used for next reaction directly. MS (ESI⁺) m/z 797.5 (M + H)⁺.

[00207] To a solution of the above compound in THF (10 mL) and DMF (5 mL) was added piperidine (0.570 mL, 5.76 mmol). The reaction mixture was stirring at RT for 1 h. The reaction was concentrated in vacuo. The residue was suspended in MeOH. The white solid formed was removed by filtration. The filtrate was concentrated and purified by flash chromatography to give (S)-tert-butyl 5-(4-((S)-2-((S)-2-amino-3-methylbutanamido)-5-ureidopentanamido)benzyl)-3,3-dimethyl-2-oxopyrrolidine-1-carboxylate **63** as a colorless foamy solid (610 mg, 92 % yield for two steps). ¹H NMR (400MHz, CDCl₃) δ 9.27 (s, 1H), 8.10 (d, *J* = 8.7 Hz, 1H), 7.58 (d, *J* = 8.4 Hz, 2H), 7.13 (d, *J* = 8.4 Hz, 2H), 5.25 (br. s., 1H), 4.82 (td, *J* = 9.0, 4.3 Hz, 1H), 4.61 (br. s., 2H), 4.25 - 4.14 (m, 1H), 3.54 (dd, *J* = 14.3, 6.8 Hz, 1H), 3.40 (dd, *J* = 13.1, 3.3 Hz, 1H), 3.32 (d, *J* = 4.0 Hz, 1H), 3.24 (dd, *J* = 14.3, 5.7 Hz, 1H), 2.61 (dd, *J* = 13.1, 9.8 Hz, 1H), 2.31 (td, *J* = 6.8, 4.0 Hz, 1H), 2.01 (dd, *J* = 13.8, 4.7 Hz, 1H), 1.84 - 1.75 (m, 2H), 1.74 - 1.63 (m, 5H), 1.61 (s, 9H), 1.21 (s, 3H), 1.15 (s, 3H), 1.03 (d, *J* = 7.0 Hz, 3H), 0.88 (d, *J* = 7.0 Hz, 3H). MS (ESI⁺) *m/z* 575.5 (M + H)⁺.

[00208] To a solution of compound **63** (610 mg, 1.06 mmol) in THF (5 mL) and MeOH (5 mL) was added lithium hydroxide, 1 M in water (63.5 mg, 2.65 mmol). The reaction mixture was stirred at RT for 2 h. The reaction mixture was acidified to pH 2-3 with 1N HCl, and concentrated with a rotary evaporator to remove the organic solvents. The residue was lyophilized to dryness to give (5)-5-(4-((5)-2-((5)-2-amino-3-methylbutanamido)-5-ureidopentanamido)phenyl)-4-((tert-butoxycarbonyl)amino)-2,2-dimethylpentanoic acid **64** as a tan solid (593 mg, 94%). MS (ESI⁺) *m/z* 593.6 (M + H)⁺.

[00209] To a solution of acid **64** (592 mg, 1.00 mmol) in THF (2 mL) were added 2,5-dioxopyrrolidin-1-yl 6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoate **65** (Cheng *et al.* 2013, 339 mg, 1.10 mmol) and DIEA (0.524 mL, 3.00 mmol). DMF (0.5 mL) was added to solubilize the reaction mixture. The reaction was stirred at RT for 5 h, and diluted with cold 0.5N aqueous HCl solution (10 mL). The precipitate formed was collected by filtration to give crude product (510 mg, 65%). MS (ESI⁺) *m/z* 786.7 (M + H)⁺.


[00210] To a solution of the above product (370 mg, 0.471 mmol) in DCM (1.5 mL) was added TFA (0.5 mL). The reaction mixture was stirred at RT for 1 h and concentrated on a rotary evaporator. The residue was dissolved in CH₃CN/water and purified by preparative HPLC (CI 8 Phenomenex Luna S5 ODS 21 x 100 mm reverse phase prep HPLC column eluting with 10-90% aq. CH₃CN containing 0.05% TFA over a 12 minute gradient) to give (5)-4-amino-5-(4-((5)-2-((5)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamido)-3-

methylbutanamido)-5-ureidopentanamido)phenyl)-2,2-dimethylpentanoic acid **66** as a white solid (240 mg, 64%). ^1H NMR (400MHz, CD_3OD) δ 9.83 (s, 1H), 8.25 (d, $J = 7.3$ Hz, 1H), 7.98 (d, $J = 7.8$ Hz, 1H), 7.61 (dd, $J = 8.4, 1.8$ Hz, 2H), 7.24 (d, $J = 8.4$ Hz, 2H), 6.81 (s, 2H), 4.59 - 4.46 (m, 1H), 4.22 - 4.11 (m, 2H), 3.50 (t, $J = 7.1$ Hz, 3H), 3.25 - 3.09 (m, 2H), 2.89 (dd, $J = 12.0, 7.4$ Hz, 2H), 2.30 (t, $J = 7.4$ Hz, 2H), 2.15 - 2.04 (m, 1H), 1.99 - 1.87 (m, 2H), 1.80 - 1.56 (m, 8H), 1.38 - 1.29 (m, 8H), 1.23 (s, 3H), 1.09 (s, 3H), 0.99 (d, $J = 6.7$ Hz, 6H); MS (ESI⁺) m/z 686.6 (M + H)⁺.

[00211] To a solution of thiazole acid **10** (Example 2, 36.6 mg, 0.054 mmol) in DMF (1.0 mL) were added HATU (20.44 mg, 0.054 mmol) and DIEA (0.028 mL, 0.161 mmol). The reaction mixture was stirred at RT for 20 min, and then added to a solution of compound **66** (43 mg, 0.054 mmol) in 0.3 ml of DMF. The resulting mixture was stirred at RT for 1.0 h and purified by preparative HPLC (CI 8 Phenomenex Luna S5 ODS 21 x 100 mm reverse phase prep HPLC column eluting with 10-90% aq. CH_3CN containing 0.05% TFA over a 12 minute gradient) to give compound (**IIIa-2**) as a white solid (47 mg, 64%>). ^1H NMR (400MHz, CD_3OD) δ 9.75 (s, 1H), 8.81 (d, $J = 8.3$ Hz, 1H), 8.24 (d, $J = 7.1$ Hz, 1H), 8.14 (s, 1H), 7.98 (d, $J = 7.7$ Hz, 1H), 7.90 (br. s., 1H), 7.50 (d, $J = 8.4$ Hz, 2H), 7.18 (d, $J = 8.4$ Hz, 2H), 6.81 (s, 2H), 5.71 (d, $J = 11.1$ Hz, 1H), 4.69 - 4.59 (m, 1H), 4.48 - 4.42 (m, 1H), 4.28 - 4.16 (m, 1H), 3.91 (d, $J = 11.1$ Hz, 1H), 3.50 (t, $J = 7.1$ Hz, 2H), 3.25 - 3.07 (m, 5H), 2.91 - 2.78 (m, 3H), 2.68 (s, 3H), 2.29 (t, $J = 7.4$ Hz, 3H), 2.19 (s, 3H), 2.01 - 1.86 (m, 7H), 1.81 - 1.54 (m, 14H), 1.37 - 1.30 (m, 5H), 1.23 (s, 3H), 1.21 (s, 3H), 1.08 - 0.88 (m, 20H); MS (ESI⁺) m/z 1234.8 (M + H)⁺.

Example 8 - Compound (IIIa-4)

(IIIa 4)



[00212] The synthesis of compound (**IIIa-4**) is described schematically by **Figs. 7a** and **7b** in combination.

[00213] DCC (0.755 g, 3.66 mmol) was added to a mixture of compound **11** (1 g, 3.33 mmol), (S)-2-((tert-butoxycarbonyl)amino)-3-ethylpentanoic acid **70** (0.898 g, 3.66 mmol) and *t*-butanol hydrate (0.510 g, 3.33 mmol) in DCM (15 mL) at 0 °C. The reaction mixture was allowed to warm up to RT and stirred at RT overnight. The solid was filtered off, and the
5 filtrate was concentrated. The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-10% MeOH in DCM to afford 1.14 g of methyl 2-((6S,9R,1 IR)-1-isopropyl-2,2-dimethyl-4,7-dioxo-6-(pentan-3-yl)-3,8-dioxa-5,12-diazapentadecan-9-yl)thiazole-4-carboxylate **71** as a colorless oil. MS: (+) m/z 528.3 (M+1).

[00214] A solution of compound **71** (0.9 g, 1.705 mmol) in *o*-xylene (5.1 mL) was heated
10 at 120 °C overnight. The solvent was evaporated off. The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-100% EtOAc in hexanes to afford 0.44 g of methyl 2-((1R,3R)-3-((S)-2-((tert-butoxycarbonyl)amino)-3-ethyl-N-propylpentanamido)-1-hydroxy-4-methylpentyl)thiazole-4-carboxylate **72** as a light yellow solid. MS: (+) m/z 528.3 (M+1).

[00215] TFA (3 mL, 0.834 mmol) was added to a solution of compound **72** (0.44 g, 0.834 mmol) in DCM (6 mL). After the reaction mixture was stirred at RT for 30 min, it was concentrated by removal of solvent, diluted with EtOAc, and washed once with saturated aqueous NaHCO₃. The aqueous solution was back-extracted twice with EtOAc. The combined organic layers were dried, filtered, and concentrated to afford 0.357 g of methyl 2-
20 ((1R,3R)-3-((S)-2-amino-3-ethyl-N-propylpentanamido)-1-hydroxy-4-methylpentyl)thiazole-4-carboxylate **73** as a white froth. MS: (+) m/z 428.3 (M+1).

[00216] DIEA (0.098 mL, 0.561 mmol) was added to a solution of compound **73** (0.24 g, 0.561 mmol) and (R)-perfluorophenyl 1-methylpiperidine-2-carboxylate **74** (0.868 g, 2.81 mmol) in DMF (3 mL) at RT. The reaction mixture was stirred at RT for 3 h. EtOAc (30
25 mL) was then added and the organic solution was washed with saturated aqueous NaHCO₃ and brine, dried, filtered and concentrated. The crude product was purified by flash chromatography, eluting from silica gel with a gradient of 0-10% MeOH in DCM to afford 0.178 g of methyl 2-((1R,3R)-3-((S)-3-ethyl-2-((R)-1-methylpiperidine-2-carboxamido)-N-propylpentanamido)-1-hydroxy-4-methylpentyl)thiazole-4-carboxylate **75** as a light yellow
30 oil. MS: (+) m/z 553.3 (M+1).

[00217] LiOH (0.031 g, 1.291 mmol) in water (0.5 mL) was added to a solution of compound **75** (0.1784 g, 0.323 mmol) in THF (1 mL) at rt. After the reaction mixture was

stirred at RT for 2 h, the solvent was evaporated. The crude product was purified by flash chromatography, eluting from silica gel with a gradient of 0-30% MeOH in DCM to afford 120 mg of 2-((1R,3R)-3-((S)-3-ethyl-2-((R)-1-methylpiperidine-2-carboxamido)-N-propylpentanamido)-1-hydroxy-4-methylpentyl)thiazole-4-carboxylic acid **76** as a white solid. MS: (+) m/z 539.3 (M+).


5 [00218] A solution of compound **76** (0.121 g, 0.223 mmol) in pyridine (1.8 mL) was cooled in an ice-water bath and acetic anhydride (0.105 mL, 1.14 mmol) was added. The reaction mixture was allowed to warm up to RT and stirred at RT overnight. A 1:1 (v/v) solution of degassed water and THF (8 mL) was added after the reaction mixture was cooled
10 in an ice-water bath. The reaction mixture was then stirred at RT overnight. The solvent was evaporated off. The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-30% MeOH in DCM to afford 100 mg of 2-((1R,3R)-1-acetoxy-3-((S)-3-ethyl-2-((R)-1-methylpiperidine-2-carboxamido)-N-propylpentanamido)-4-methylpentyl)thiazole-4-carboxylic acid **77** as a white solid. MS: (+) m/z 581.3 (M+).

15 [00219] DIEA (4.17 μ l, 0.024 mmol) was added to a solution of compound **77** (13.89 mg, 0.024 mmol) and HATU (9.09 mg, 0.024 mmol) in DMF (0.5 mL). The pH of the reaction mixture was adjusted to 8-9. After the reaction mixture was stirred at RT for 10 min, compound **66** (16.4 mg, 0.024 mmol) in DMF (1 mL) and DIEA (4.17 μ l, 0.024 mmol) were added. The pH of the reaction mixture was adjusted to 8-9. After the reaction mixture was
20 stirred at RT for 20 min, the reaction was quenched by addition of 10 mL 1:1 (v/v) mixture of water containing 0.1% TFA and acetonitrile. The product compound (**IIIa-4**) was purified by preparative HPLC. MS: (+) m/z 1248.7 (M+).

[00220] Compound (**Ia-4**) can be prepared from compound (**IIIa-4**) by removal of the linker, for example by cleavage with cathepsin B.

wet loading on a C-18 reverse phase 50 gram Gold ISCO column, eluting with 40-100% aq CH₃CN with 0.1% TFA over a 12 minute gradient. The appropriate fractions were isolated and freeze dried to afford analog-linker **(IIIc-1)** (0.008 gm, 38%) as a white solid. ¹H NMR (400MHz, acetonitrile-d₃) δ 8.02 - 7.87 (m, 1H), 7.40 - 7.13 (m, 5H), 6.84 - 6.61 (m, 2H),
 5.77 - 5.58 (m, 1H), 4.67 - 4.53 (m, 2H), 4.46 - 4.28 (m, 2H), 3.51 - 3.24 (m, 2H), 3.10 - 2.52
 5 (m, 7H), 2.31 - 2.08 (m, 9H), 1.92 - 1.83 (m, 1H), 1.74 - 1.49 (m, 6H), 1.38 - 1.25 (m, 2H),
 1.21 - 1.02 (m, 10H), 1.00 - 0.66 (m, 21H); MS (ESI⁺) m/z 952.0 (M+H)⁺.

Example 12 - Compound (IIIc-3)



10 [00225] Figs. 8a and 8b show, in combination, a scheme for making compound **(IIIc-2)**.

[00226] (R)-2-((Tert-butoxycarbonyl)(methyl)amino)-3-methylbutanoic acid **80** (1 g, 4.32 mmol), phenylmethanol **81** (0.447 mL, 4.32 mmol), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (0.647 g, 4.76 mmol) and N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine (0.738 g, 4.76 mmol) were dissolved in DMF (3 mL) and the resulting solution was then
 15 treated with DIEA (3.01 mL, 17.29 mmol) at RT. The resulting reaction mixture was stirred at RT for 48 h. The crude reaction mixture was wet loaded on to a C-18 reverse phase 50 gm gold ISCO column, eluting 40-100% aq CH₃CN with 0.1% TFA over a 13 min gradient. The appropriate fractions were isolated and quenched with aq. NaCl. The solution was extracted with DCM (3x). The combined organic extracts were dried with anhydrous sodium sulfate,
 20 filtered and the filtrate concentrated *in vacuo* to afford (R)-benzyl 2-((tert-butoxycarbonyl)-(methyl)amino)-3-methylbutanoate **82** (0.63 gm, 45%) as an oil. ¹H NMR (400MHz, chloroform-d) δ 7.35 (s, 5H), 5.17 (br. s., 2H), 4.52 (d, *J*=10.6 Hz, 1H), 4.16 (d, *J*=10.6 Hz, 1H), 2.92 - 2.69 (m, 3H), 2.20 (br. s., 1H), 1.45 (d, *J*=14.3 Hz, 9H), 0.97 (d, *J*=6.6 Hz, 3H), 0.90 (d, *J*=6.4 Hz, 3H); MS (ESI⁺) m/z 322.1 (M+H)⁺.

[00227] Compound **82** (0.63 g, 1.960 mmol) was treated with 4N HCl (4.90 mL, 19.60 mmol) in dioxane (4.9 ml) at RT. The reaction mixture was stirred at RT for 2h and then concentrated *in vacuo*. The solid was further dried under high vacuum to afford (R)-benzyl 3-methyl-2-(methylamino)butanoate **83** (0.50 gm, 99%) as solid HCl salt. ¹H NMR (400MHz, methanol-d₄) δ 7.48 - 7.27 (m, 5H), 5.44 - 5.17 (m, 2H), 3.97 (d, *J*=4.0 Hz, 1H), 2.73 (s, 3H), 2.30 (td, *J*=7.0, 4.1 Hz, 1H), 1.11 - 0.81 (m, 6H); MS (ESI⁺) *m/z* 222.1 (M+H)⁺.

[00228] (9H-fluoren-9-yl)methyl ((S)-1-(((S)-1-((4-(hydroxymethyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate **84** (0.5 g, 0.831 mmol) was dissolved in DMF (5 mL) and compound **53a** (0.506 g, 1.662 mmol) was added, followed by DIEA (0.23 mL, 1.320 mmol) at RT. The reaction mixture was stirred for 1.5 h at RT. LC/MS showed no starting material was left. The reaction mixture was then treated with 30 mL of Et₂O and stirred at RT for 30 min. The precipitate that formed was filtered and washed with additional Et₂O. The solid was dried under high vacuum to afford (9H-fluoren-9-yl)methyl ((S)-3-methyl-1-(((S)-1-((4-(((4-nitrophenoxy)carbonyl)oxy)methyl)-phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-1-oxobutan-2-yl)carbamate **85** (0.533 gm, 84%) as an off yellow solid. ¹H NMR (400MHz, DMSO-d₆) δ 10.12 (s, 1H), 8.37 - 8.22 (m, 2H), 8.12 (d, *J*=7.5 Hz, 1H), 7.88 (d, *J*=7.5 Hz, 2H), 7.76 - 7.50 (m, 5H), 7.44 - 7.15 (m, 7H), 5.96 (t, *J*=5.5 Hz, 1H), 5.39 (s, 2H), 5.24 (s, 2H), 4.49 - 4.39 (m, 1H), 4.34 - 4.10 (m, 3H), 3.93 (dd, *J*=8.8, 7.3 Hz, 1H), 3.13 - 2.82 (m, 2H), 2.05 - 1.88 (m, 1H), 1.75 - 1.53 (m, 2H), 1.50 - 1.28 (m, 2H), 0.87 (dd, *J*=11.1, 6.7 Hz, 6H); MS (ESI⁺) *m/z* 767.3 (M+H)⁺.

[00229] Compound **85** (0.11 g, 0.143 mmol) was dissolved in DMF (1 mL) and the resulting solution was then treated with compound **83** (hydrochloride, 0.11 g, 0.427 mmol), 1H-benzo[d][1,2,3]triazol-1-ol (0.058 g, 0.430 mmol) and then with 2,6-dimethylpyridine (0.117 mL, 1.004 mmol) at RT. The resulting reaction mixture was stirred at RT for 12 h. The crude reaction mixture was wet loaded on to a C-18 reverse phase gold ISCO column eluting 50-100 % aq CH₃CN with 0.1% TFA over a 13 minute gradient. The appropriate fractions were isolated and freeze dried to afford (R)-benzyl 2-(((4-((S)-2-((S)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanamido)-benzyl)oxy)carbonyl(methyl)amino)-3-methylbutanoate **86** (0.08 gm, 65%) as a solid. ¹H NMR (400MHz, DMSO-d₆) δ 8.10 (d, *J*=7.5 Hz, 1H), 7.88 (d, *J*=7.5 Hz, 3H), 7.73 (t, *J*=7.9 Hz, 3H), 7.60 - 7.51 (m, 3H), 7.43 - 7.11 (m, 9H), 5.95 (br. s., 1H), 5.39 (br. s., 1H), 5.16 - 4.86 (m, 4H), 4.50 - 4.12 (m, 5H), 3.93 (dd, *J*=8.9, 6.9 Hz, 1H), 3.08 - 2.88 (m, 2H), 2.84 -

2.72 (m, 3H), 2.15 (br. s., 1H), 2.05 - 1.93 (m, 1H), 1.73 - 1.54 (m, 2H), 1.46 - 1.24 (m, 2H), 0.98 - 0.67 (m, 12H); MS (ESI⁺) m/z 849.6 (M+H)⁺.

[00230] Compound **86** (0.075 g, 0.088 mmol) and 10% Pd/C was treated with MeOH (2 mL). The heterogeneous mixture was then treated with triethylsilane (0.141 mL, 0.883 mmol) at RT. Once the gas evolution ceased (5 min) the reaction was complete. The reaction mixture was filtered through a bed of CELITE™ and the filtrate was concentrated *in vacuo*. The solid was further dried under high vacuum to afford (R)-2-(((4-((S)-2-((S)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methylbutanamido)-5-ureidopentanamido)-benzyl)oxy)carbonyl)(methyl)amino)-3-methylbutanoic acid **87** (0.060 gm, 85%) as a solid; MS (ESI⁺) m/z 759.4 (M+H)⁺.


[00231] Compound **87** (0.06 g, 0.079 mmol) and HATU (0.030 g, 0.079 mmol) were dissolved in 2,6-lutidine (0.037 mL, 0.316 mmol) at RT. The reaction mixture was stirred for 30 min at RT. A solution of acid **88** (0.052 g, 0.079 mmol) and 2,6-lutidine (0.037 mL, 0.316 mmol) in DMF (1 mL) was then added and the resulting reaction mixture was stirred at RT for 1 h. (Compound **88** can be prepared by coupling compounds **35** and **60** and then reducing the azide group with triphenylphosphine.) The crude reaction was wet loaded on to a 50 gm gold C-18 ISCO reverse phase column, eluting 50-100% aq CH₃CN with 0.1% TFA over a 12 minute gradient. The appropriate fractions were isolated and freeze dried to afford (S)-4-(2-((5R,8S,11R,13R)-1-(4-((S)-2-((S)-2-(((9H-fluoren-9-yl)methoxy)carbonyl)-amino)-3-methylbutanamido)-5-ureidopentanamido)phenyl)-8-((S)-sec-butyl)-5,11-diisopropyl-4-methyl-3,6,9,15-tetraoxo-10-propyl-2,14-dioxo-4,7,10,16-tetraazaheptadecan-13-yl)thiazole-4-carboxamido)-2,2-dimethyl-5-phenylpentanoic acid **89** (0.038 gm, 34%) as a solid. ¹H NMR (400MHz, DMSO-*d*₆) δ 10.09 - 9.92 (m, 1H), 8.36 (br. s., 1H), 8.08 (br. s., 2H), 7.88 (s, 5H), 7.61 - 6.96 (m, 10H), 5.96 (d, *J*=5.7 Hz, 1H), 5.65 - 5.49 (m, 1H), 5.38 (br. s., 2H), 4.98 (br. s., 2H), 4.59 - 4.09 (m, 9H), 3.93 - 3.81 (m, 1H), 3.10 - 2.94 (m, 2H), 2.87 - 2.68 (m, 4H), 2.57 (d, *J*=4.6 Hz, 4H), 2.32 (d, *J*=1.8 Hz, 3H), 2.16 - 1.80 (m, 6H), 1.74 - 1.11 (m, 11H), 1.06 - 0.95 (m, 5H), 0.92 - 0.56 (m, 27H); MS (ESI⁺) m/z 1400.2 (M+H)⁺.

[00232] Compound **89** (0.038 g, 0.027 mmol) was dissolved in DMF (1 mL) with piperidine (0.2 ml, 2.025 mmol). The resulting reaction mixture was stirred at RT for 1 h and purified by wet loading on a C-18 reverse phase ISCO 50 gm gold column, eluting 10-100% aq acetonitrile with 0.1% TFA over a 12 min gradient. The appropriate fractions were isolated and freeze dried to afford (S)-4-(2-((5R,8S,11R,13R)-1-(4-((S)-2-((S)-2-amino-3-


[00234] Analog-linker compound (**IIIc-2**) was prepared from compound **87** of the previous example and compound **39**, generally following the same procedure of the previous example. The analytical properties of compound (**IIIc-2**) were: ^1H NMR (400MHz, acetonitrile- d_3) δ 8.93 (br. s., 1H), 8.00 - 7.88 (m, 1H), 7.76 - 7.56 (m, 1H), 7.41 - 7.05 (m, 9H), 6.68 (d, $J=7.3$ Hz, 2H), 5.76 (d, $J=11.2$ Hz, 1H), 4.96 (br. s., 2H), 4.61 (br. s., 1H), 4.50 (br. s., 1H), 4.38 (br. s., 1H), 4.20 - 3.97 (m, 3H), 3.59 (br. s., 1H), 3.43 (t, $J=7.0$ Hz, 3H), 3.29 - 3.18 (m, 1H), 3.13 - 3.03 (m, 1H), 2.96 - 2.84 (m, 2H), 2.80 (br. s., 4H), 2.54 (br. s., 3H), 2.33 - 2.17 (m, 2H), 2.10 - 2.09 (m, 1H), 2.01 - 1.44 (m, 20H), 1.35 - 1.01 (m, 10H), 0.98 - 0.55 (m, 27H); MS (ESI $^+$) m/z 1375.5 (M+H) $^+$.

10 *Example 14 - Biologic Activity of Compounds*


[00235] The cytotoxic activity of compounds of this invention is shown in Table II. The cancer cells lines tested against were: H226 (human lung cancer); N87 (human gastric cancer), OVCAR3 (human ovarian cancer), HCT1 16 (human colon cancer), HCT1 16/VM46 (HCT1 16 subline with multi-drug resistance, including to paclitaxel), and ACR (human breast cancer, multi-drug resistant). Table II also includes comparative data against reference compounds (A)-(G) not according to this invention:




(B) $\text{R}^{45} = \text{NH}_2$



(D) $\text{R}^{46} = \text{OH}$



20



[00236] The ability of test compounds to inhibit cell proliferation was measured by either an ATP luminescence assay or an MTS cell proliferation assay. These two methods yield comparable results. In some instances, both methods were used.

5 [00237] This is a general procedure for an ATP luminescence assay: Cells are seeded at 1×10^3 cells/well in 96-well plates for 3 h for ATP CellTiterGlo™ assays, respectively. Serial dilutions (1:3) of compounds are added to the wells. Plates are allowed to incubate for 72 h. A CellTiterGlo™ cell viability kit from Promega is used to measure ATP content of cells treated with test compounds following manufacturer's instruction. A decrease in the ATP
 10 content is a measure of decrease in cellular viability. The EC50 value - the concentration at which an agent reduces cell viability by 50% of the maximum effect - is determined using PRISM™ software, version 5.0 (GraphPad Software, La Jolla, CA, USA).

[00238] The following is a description of the MTS cell proliferation assay: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit from Promega (Madison, WI) is used to
 15 determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at $40 \mu L$ per well and incubated overnight at $37^\circ C$ in $5\% CO_2$ before assaying. On the next day, one set of cell plates (TO plates) is used to determine time zero cell density, and 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium is added at $4 \mu L$ /well
 20 into TO plates followed by incubation at $37^\circ C$ in $5\% CO_2$ for three hours. This tetrazolium reagent is bio-reduced by liver cells to form a formazan product which is soluble in aqueous solution. Absorbance at 490 nm is measured on an Envision reader (Perkin Elmer, Boston, MA). On the same day, compounds are added into remaining cell plates (T72 plates) and incubated at $37^\circ C$ in $5\% CO_2$. After 72 hours, $4 \mu L$ MTS reagents are then added into those
 25 cell plates. The plates are further incubated at $37^\circ C$ in $5\% CO_2$ for three hours and the absorbance values at A490 were measured on an Envision reader.

Table II - Activity of Tubulysin Analogs Against Cancer Cell Lines						
Compound	Cancer Cell Line: EC50 (nM)					
	H226	N87	OVCAR3	HCT1 16	HCT1 16/ VM46	ADR
(Ia-1)	0.089	0.03 to 0.20	0.016 to 0.04			
(Ia-2)	0.33 to 1.1	0.65 to 1.0	0.07 to 0.1	0.58	1.22	9.5
(Ia-3)	0.086	0.16	0.019	0.13	0.19	
(Ib-1)	0.63	1.7	0.07			
(Ib-2)	0.4	4.4	0.15			
(Ic-1)	0.038	0.20	0.012	0.064	0.51	
(Ic-2))	0.31	0.37	0.04	0.26	7.5	
(A)	2.4	3.2	0.46			
(B)	85	106	57	200	>250	
(C)	3.3					86
(D)	11	10	1.0			33
(E)	28					189
(F)	78					
(G)	27					383

Example 15 - Biological activity of conjugates

[00239] Analog-linker compounds (IIa- 1)-(IIIa-4) and (IIIc- 1)-(IIIc-3) were conjugated to an anti-CD70 human monoclonal antibody and tested for activity against 786-0 renal cancer cells, using a ³H thymidine assay (Cong *et al.* 2014). The results are provided in Table III.

Table III - Activity of Conjugates against 786-0 Renal Cancer Cells		
Conjugate	DAR	IC ₅₀ (nM)
(IIIa-1)-CD70	2	0.34
(IIIa-2)-CD70	1.8	0.21
(IIIa-3)-CD70	3.3	0.20
(IIIa-4)-CD70	3.1	0.23
(IIIc-2)-CD70	2.1	0.64
(IIIc-3)-CD70	2.4	1.5

[00240] Analog-linker compounds (IIa- 1)-(IIIa-4) and (IIIc- 1)-(IIIc-3) were conjugated to an anti-mesothelin human monoclonal antibody and tested for activity against N87 gastric cancer cells, using a ³H thymidine assay (Cong *et al.* 2014). The results are provided in Table IV.

Table IV - Activity of Conjugates against N87 Gastric Cancer Cells		
Conjugate	DAR	IC ₅₀ (nM)
(IIIa-1)-CD70	3.5	0.14
(IIIa-2)-CD70	2.2	0.24
(IIIa-3)-CD70	2.8	0.10
(IIIa-4)-CD70	3.1	0.25
(IIIc-2)-CD70	2.3	6
(IIIc-3)-CD70	2.4	5.7

5

[00241] The foregoing detailed description of the invention includes passages that are chiefly or exclusively concerned with particular parts or aspects of the invention. It is to be understood that this is for clarity and convenience, that a particular feature may be relevant in more than just the passage in which it is disclosed, and that the disclosure herein includes all the appropriate combinations of information found in the different passages. Similarly, although the various figures and descriptions herein relate to specific embodiments of the invention, it is to be understood that where a specific feature is disclosed in the context of a particular figure or embodiment, such feature can also be used, to the extent appropriate, in the context of another figure or embodiment, in combination with another feature, or in the invention in general.

15

[00242] Further, while the present invention has been particularly described in terms of certain preferred embodiments, the invention is not limited to such preferred embodiments. Rather, the scope of the invention is defined by the appended claims.

REFERENCES

[00243] Full citations for the references cited in abbreviated fashion by first author (or inventor) and date earlier in this specification are provided below. Each of these references is incorporated herein by reference for all purposes. The citation of a reference hereinbelow or elsewhere in this specification is not an admission that such reference is material prior art.

[00244] Abe *et al.*, WO 97/21712 (1997).

- [00245] Boyd *et al*, US 2008/0279868 A1 (2008).
- [00246] Boyd *et al*, US 7,691,962 B2 (2010).
- [00247] Balasubramanian *et al*, *Bioorg. Med. Chem. Lett.* **2008**, 18, 2996.
- [00248] Balasubramanian *et al.*, *J. Med. Chem.* **2009**, 52 (2), 238.
- 5 [00249] Chai *et al*, *Chem. & Biol* **2010**, 17(3), 296.
- [00250] Chai *et al*, US 201 1/0245295 A1 (201 1).
- [00251] Cheng *et al*, US 8,394,922 B2 (2013).
- [00252] Coccia *et al* , US 2010/0150950 (2010).
- [00253] Cong *et al*, US 2014/0227295 A1 (2014).
- 10 [00254] Davis *et al*, US 2008/0176958 A1 (2008).
- [00255] Domling, DE 10 2004 030 227 A1 (2006).
- [00256] Domling *et al*, US 2005/0239713 A1 (2005) [2005a].
- [00257] Domling *et al*, US 2005/0249740 A1 (2005) [2005b].
- [00258] Domling *et al.*, *Mol. Diversity* **2005**, 9, 141 [2005c].
- 15 [00259] Domling *et al*, *Ang. Chem. Int. Ed.* **2006**, 45, 7235.
- [00260] Ellman *et al*, US 8,476,451 B2 (2013).
- [00261] Hamel *et al*, *Curr. Med. Chem. - Anti-Cancer Agents* **2002**, 2, 19.
- [00262] Hoefle *et al*, DE 100 08 089 A1 (2001).
- [00263] Hoefle *et al*, *Pure Appl Chem.* **2003**, 75 (2-3), 167.
- 20 [00264] Hoefle *et al*, US 2006/0128754 A1 (2006) [2006a].
- [00265] Hoefle *et al*, US 2006/0217360 A1 (2006) [2006b].
- [00266] Jackson *et al*, US 2013/0224228 A1 (2013).
- [00267] Kaur *et al*, *Biochem. J.* **2006**, 396, 235.
- [00268] Khalil *et al*, *ChemBioChem* **2006**, 7, 678.
- 25 [00269] Leamon *et al*, *Cancer Res.* **2008**, 68 (23), 9839.


- [00270] Leamon *et al*, US 2010/0323973 A1 (2010).
- [00271] Leamon *et al.*, US 2013/0116915 A1 (2013).
- [00272] Leung *et al*, US 2002/0169125 A1 (2002).
- [00273] Low *et al*, US 2010/0324008 A1 (2010).
- 5 [00274] Lundquist *et al*, *Org. Lett.* **2001**, 3, 781.
- [00275] Mammen *et al*, US 2013/0323271 A1 (2013).
- [00276] Miao *et al*, WO 2013/173393 A1 (2013).
- [00277] Neri *et al*, *ChemMedChem* **2006**, 1, 175.
- [00278] Pando *et al*, *J. Am. Chem. Soc.* **2011**, 133, 7692.
- 10 [00279] Patterson *et al*, *Chem. Eur. J.* **2007**, 13, 9534.
- [00280] Patterson *et al.*, *J. Org. Chem.* **2008**, 73, 4362.
- [00281] Peltier *et al*, *J. Am. Chem. Soc.* **2006**, 128, 16018.
- [00282] Raghavan *et al.*, *J. Med. Chem.* **2008**, 51, 1530.
- [00283] Reddy *et al.*, *Mol. Pharmaceutics* **2009**, 6 (5), 1518.
- 15 [00284] Reichenbach *et al.* WO 98/13375 A1 (1998).
- [00285] Richter, US 2012/0129779 A1 (2012) [2012a]
- [00286] Richter, US 2012/0252738 A1 (2012) [2012b].
- [00287] Richter, US 2012/0252739 A1 (2012) [2012c].
- [00288] Sani *et al.*, *Angew. Chem. Int. Ed.* **2007**, 46, 3526.
- 20 [00289] Sasse *et al.*, *J. Antibiotics* **2000**, 53 (9), 879.
- [00290] Sasse *et al*, *Nature Chem. Biol.* **2007**, 3 (2), 87.
- [00291] Schluep *et al*, *Clin. Cancer Res.* **2009**, 15 (1), 181.
- [00292] Schrama *et al*, *Nature Rev. Drug Disc.* **2006**, 5, 147.
- [00293] Shankar *et al*, *SYNLETT* **2009**, 8, 1341-1345.
- 25 [00294] Shankar *et al*, *Org. Biomol. Chem.*, **2013**, 11(14), 2273.

- [00295] Shibue *et al*, *Tetrahedron Lett.* **2009**, 50, 3845.
- [00296] Shibue *et al*, *Chemistry Eur. J* , **2010**, 16(38), 11678.
- [00297] Shibue *et al*, *Bioorg. Med. Chem.*, **2011**, 21, 431.
- [00298] Sreejith *et al*, *SYNLETT2011*, No. 12, 1673.
- 5 [00299] Steinmetz *et al* ,*Angew. Chem. Int. Ed.* **2004**, 43, 4888.
- [00300] Terrett *et al*, US 8,268,970 B2 (2012).
- [00301] Terrette *et al*, US 2010/0209432 A1 (2010).
- [00302] Ullrich *et al* ,*Angew. Chemie Int. Ed.* **2009**, 48, 4422.
- [00303] Vlahov *et al*, *Bioorg. Med. Chem. Lett.* **2008**, 18 (16), 4558 [2008a].
- 10 [00304] Vlahov *et al*, US 2008/0248052 A1 (2008) [2008b].
- [00305] Vlahov *et al*, US 2010/0240701 A1 (2010) [2010a].
- [00306] Vlahov *et al*, US 2010/0048490 A1 (2010) [2010b].
- [00307] Vlahov *et al*, *Bioorg. Med. Chem. Lett.* **2011**, 21, 6778.
- [00308] Vlahov *et al* , US 2014/0107316 A1 (2014) [2014a].
- 15 [00309] Vlahov *et al*, WO 2014/078484 A1 (2014) [2014b].
- [00310] Wang *et al*, *Chem. Biol Drug. Des.* **2007**, 70, 75.
- [00311] Wessjohann *et al*, US 2013/0217638 A1 (2013).
- [00312] Wipf *et al*, *Org. Lett.* **2004**, 6 (22), 4057.
- [00313] Wipf *et al*, *Org. Lett.* **2007**, 9 (8), 1605.
- 20 [00314] Wipf *et al*, US 2010/0047841 A1 (2010).
- [00315] Zanda *et al*, US 8,580,820 B2 (2013).
- [00316] Zhao *et al*, WO 2014/009774 A1 (2014) [2014a].
- [00317] Zhao *et al*, WO 2014/080251 A1 (2014) [2014b].


CLAIMS

What is claimed is:

1. A tubulysin analog having a structure represented by formula (I)



5 wherein



wherein

R^{1a} is H, Ci-C₅ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl, CO(Ci-C₅ alkyl), CO(C₂-C₅ alkenyl), or CO(C₂-C₅ alkynyl);

10 each R^{1b} is independently H or C₁₋₃ alkyl;


R^{1c} is H, Me, or CH(Me)₂; and

n is 0, 1, or 2;


R² is H, unsubstituted or substituted Ci-C₁₀ alkyl, unsubstituted or substituted C₂-C₁₀ alkenyl, unsubstituted or substituted C₂-C₁₀ alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted (CH₂)_{i-2}O(Ci-C₁₀ alkyl), unsubstituted or substituted (CH₂)_{i-2}O(C₂-C₁₀ alkenyl), unsubstituted or substituted (CH₂)_{i-2}O(C₂-C₁₀ alkynyl), (CH₂)_{i-2}OC(=O)(Ci-C₁₀ alkyl), unsubstituted or substituted (CH₂)_{i-2}OC(=O)(C₂-C₁₀ alkenyl), unsubstituted or substituted (CH₂)_{i-2}OC(=O)(C₂-C₁₀ alkynyl), unsubstituted or substituted C(=O)(Ci-C₁₀ alkyl), unsubstituted or substituted C(=O)(C₂-C₁₀ alkenyl), unsubstituted or substituted C(=O)(C₂-C₁₀ alkynyl), unsubstituted or substituted cycloaliphatic, unsubstituted or substituted heterocycloaliphatic, unsubstituted or substituted arylalkyl, or unsubstituted or substituted alkylaryl;

15
20
25 R³ is H, unsubstituted or substituted C₁-C₁₀ alkyl, unsubstituted or substituted C₂-C₁₀ alkenyl, unsubstituted or substituted C₂-C₁₀ alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted (CH₂)_{i-2}O(Ci-C₁₀

alkyl), unsubstituted or substituted $(\text{CH}_2)_{1-20}(\text{C}_2\text{-Cio alkenyl})$, unsubstituted or substituted $(\text{CH}_2)_{1-20}(\text{C}_2\text{-Cio alkynyl})$, $(\text{CH}_2)_{1-20}\text{OC}(=\text{O})(\text{Ci-Cio alkyl})$, unsubstituted or substituted $(\text{CH}_2)_{1-20}\text{C}(=\text{O})(\text{C}_2\text{-Cio alkenyl})$, unsubstituted or substituted $(\text{CH}_2)_{1-20}\text{OC}(=\text{O})(\text{C}_2\text{-Cio alkynyl})$, unsubstituted or substituted $\text{C}(=\text{O})(\text{Ci-Cio alkyl})$, unsubstituted or substituted $\text{C}(=\text{O})(\text{C}_2\text{-Cio alkenyl})$, unsubstituted or substituted $\text{C}(=\text{O})(\text{C}_2\text{-Cio alkynyl})$, unsubstituted or substituted cycloaliphatic, unsubstituted or substituted heterocycloaliphatic, unsubstituted or substituted arylalkyl, unsubstituted or substituted alkylaryl, or



wherein each R^{3a} is independently H, NH_2 , NHMe , Cl, F, Me, Et, or CN;



wherein

R^{4a} and R^{4b} are independently H, C1-C5 alkyl, $\text{CH}_2(\text{C}_5\text{-C}_6 \text{ cycloalkyl})$, $\text{CH}_2\text{C}_6\text{H}_5$, C_6H_5 , or $\text{CH}_2\text{CH}_2\text{OH}$; and

W is O or S;


R^5 and R^6 are each Me or combine with the carbon to which they are bonded to form a cyclopropyl ring;

R^7 is H or C1-C3 alkyl; and

Y is H, OH, Cl, F, CN, Me, Et, NO_2 , or NH_2 ;

or a pharmaceutically acceptable salt thereof.

2. A tubulysin analog according to claim 1, having a structure represented by formula (Ia):




wherein


R² is Me, Et, CH₂CH₂CH₃, CH(Me)₂, CH(Et)₂, or  ;

R³ is H, Ci-C₅ alkyl, Ci-C₅ alkenyl, Ci-C₅ alkynyl, CH₂OC(=O)Ci-C₅ alkyl, CH₂OC(=O)Ci-C₅ alkenyl, or CH₂OC(=O)Ci-C₅ alkynyl; and R⁴, R⁵, R⁶ and R⁷ are as defined in claim 1.

- 5 3. A tubulysin analog according to claim 1, having a structure represented by formula (Ia')




wherein

R² is CH(Me)₂, CH(Et)₂, or  ;


- 10 R³ is Ci-5 alkyl;
R^{4d} is Me or NHMe; and
R⁷ is H, Me, or Et.

4. A tubulysin analog according to claim 1, having a structure represented by formula (Ib')




15

wherein



R² is CH(Me)₂, CH(Et)₂, or  ;

- 20 R³ is Ci-5 alkyl;
R^{4d} is Me or NHMe; and
R⁷ is H, Me, or Et.

5. A tubulysin analog according to claim 1, having a structure represented by formula (Ic)



wherein



R^3 is Ci-5 alkyl;


R^{4d} is Me or NHMe;

10 R^5 and R^6 are each Me or combine with the carbon to which they are bonded to form a cyclopropyl ring; and

R^7 is H, Me, or Et.

6. A tubulysin analog according to claim 4, wherein R^5 and R^6 are each Me.

7. A tubulysin analog-linker compound having a structure represented by formula (IIIa):



15

or a pharmaceutically acceptable salt thereof;

wherein



R³ is H, Ci-C₅ alkyl, Ci-C₅ alkenyl, Ci-C₅ alkynyl, CH₂OC(=O)Ci-C₅ alkyl, CH₂OC(=O)Ci-C₅ alkenyl, or CH₂OC(=O)Ci-C₅ alkynyl;

R^{4d} is Me or NHMe;

R⁵ and R⁶ are each Me or combine with the carbon to which they are bonded to form a

5 cyclopropyl ring;

R⁷ is H, Me, or Et;

T is a self-immolating group;

t is 0 or 1;

AA^a and each AA^b are independently selected from the group consisting of alanine, β-


10 alanine, γ-aminobutyric acid, arginine, asparagine, aspartic acid, γ-carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;

p is 1, 2, 3, or 4;

15 q is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;


r is 1, 2, 3, 4, or 5;

s is 0 or 1; and



8. A tubulysin analog-linker compound having a structure represented by formula (IIIc):


(IIIc)



or a pharmaceutically acceptable salt thereof;

wherein

R^{1c} is H, Me, or CH(Me)₂;

R² is Me, Et, CH₂CH₂CH₃, CH(Me)₂, CH(Et)₂, or  ;

R³ is H, Ci-C₅ alkyl, Ci-C₅ alkenyl, Ci-C₅ alkynyl, CH₂OC(=O)Ci-C₅ alkyl, CH₂OC(=O)Ci-C₅ alkenyl, or CH₂OC(=O)Ci-C₅ alkynyl;

5 R^{4d} is Me orNHMe;

R⁵ and R⁶ are each Me or combine with the carbon to which they are bonded to form a cyclopropyl ring;

R⁷ is H, Me, or Et;

C is a self-immolating group;

10 c is 0 or 1;

AA^a and each AA^b are independently selected from the group consisting of alanine, β-alanine, γ-aminobutyric acid, arginine, asparagine, aspartic acid, γ-carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;


15

p is 1, 2, 3, or 4;

q is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

r is 1, 2, 3, 4, or 5;


s is 0 or 1; and



20

9. An antibody-drug conjugate having a structure represented by formula (Ha):

(IIa)



wherein

R^2 is Me, Et, $\text{CH}_2\text{CH}_2\text{CH}_3$, $\text{CH}(\text{Me})_2$, $\text{CH}(\text{Et})_2$, or  ;

R^3 is H, Ci- C_5 alkyl, Ci- C_5 alkenyl, Ci- C_5 alkynyl, $\text{CH}_2\text{OC}(=\text{O})\text{Ci-}\text{C}_5$ alkyl, $\text{CH}_2\text{OC}(=\text{O})\text{Ci-}$
5 C_5 alkenyl, or $\text{CH}_2\text{OC}(=\text{O})\text{Ci-}\text{C}_5$ alkynyl;

R^{4d} is Me or NHMe;

R^5 and R^6 are each Me or combine with the carbon to which they are bonded to form a
cyclopropyl ring;

R^7 is H, Me, or Et;

10 T is a self-immolating group;

t is 0 or 1;

AA^a and each AA^b are independently selected from the group consisting of alanine, β -
alanine, γ -aminobutyric acid, arginine, asparagine, aspartic acid, γ -carboxyglutamic
acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine,
15 leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline,
serine, threonine, tryptophan, tyrosine, and valine;


p is 1, 2, 3, or 4;

q is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

r is 1, 2, 3, 4, or 5;

20 s is 0 or 1;


Ab is an antibody;



where the open valence of R⁴⁰ that is bonded to Ab is denoted by an asterisk (*); and m is 1, 2, 3, or 4.

5 **10.** An antibody-drug conjugate having a structure represented by formula (IIc):

(IIc)



wherein

R² is Me, Et, CH₂CH₂CH₃, CH(Me)₂, CH(Et)₂, or ;

R³ is H, C₁-C₅ alkyl, Ci-C₅ alkenyl, Ci-C₅ alkynyl, CH₂OC(=O)Ci-C₅ alkyl, CH₂OC(=O)Ci-C₅ alkenyl, or CH₂OC(=O)Ci-C₅ alkynyl;

R^{4d} is Me or NHMe;

R⁵ and R⁶ are each Me or combine with the carbon to which they are bonded to form a cyclopropyl ring;

R⁷ is H, Me, or Et;

15 T is a self-immolating group;

t is 0 or 1;

AA^a and each AA^b are independently selected from the group consisting of alanine, β-alanine, γ-aminobutyric acid, arginine, asparagine, aspartic acid, γ-carboxyglutamic

acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;


p is 1, 2, 3, or 4;

5 q is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

r is 1, 2, 3, 4, or 5;

s is 0 or 1;

Ab is an antibody;



11. A method of treating cancer in a subject suffering from such cancer, comprising administering to the subject a therapeutically effective amount of a conjugate according to claim 9.

12. A method according to claim 11, wherein the cancer is renal or gastric cancer.

13. A method of treating cancer in a subject suffering from such cancer, comprising administering to the subject a therapeutically effective amount of a conjugate according to claim 10.

20 14. A method according to claim 13, wherein the cancer is renal or gastric cancer.

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5a




Fig. 6




Fig. 7a





Fig. 7b

Fig. 8a





Fig. 8b



INTERNATIONAL SEARCH REPORT

International application No PCT/US2015/059807

A. CLASSIFICATION OF SUBJECT MATTER
 INV. C97 K5/062 C07D277/24 C07 K5/078 A61P35/90
 ADD .

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 C07K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 EPO-Internal , WPI Data , BIOSIS, CHEM ABS Data , EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	wo 2014/ 126836 AI (SQUIBB BRISTOL MYERS CO [US]) 21 August 2014 (2014-08-21) paragraph [0072] paragraph [0121] paragraph [0131] ; claims 11-15 compounds III-8, 111-9, 111-10, 111-11, I11-12 -----	1, 2, 7, 9, 11-14 3-6, 8, 10
X	wo 2011/017249 AI (MEDAREX INC [US] ; CHENG HENG [US] ; CONG QIANG [US] ; GANGWAR SANJEEV [U]) 10 February 2011 (2011-02-10) page 45 - page 46; claims 1, 5-7, 9, 13; compounds 111a, 111b, 111r, 111s, Hit, I11y ----- -/--	1, 2, 9, 11

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
--	--

Date of the actual completion of the international search 13 January 2016	Date of mailing of the international search report 20/01/2016
--	--

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Jetter , Sonya
--	--

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2015/059807

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category"	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WANG Z ET AL: "Structure-activity and High-content Imaging Analysis for Novel Tubulysin", CHEMICAL BIOLOGY & DRUG DESIGN, BLACKWELL PUBLISHING TD., OXFORD, GB, vol. 70, no. 2, 1 August 2007 (2007-08-01), pages 75-86, XP002509547, ISSN: 1747-0277, DOI: 10.1111/J.1747-0285.2007.00541.X [retrieved on 2007-07-19] scheme 2;; page 85, column 1, line 1 - line 30; figure 6; table 2</p>	1, 11
X	<p>PATTERSON ANDREW W ET AL: "Design, synthesis, and biological properties of highly potent tubulysin D analogues", CHEMISTRY - A EUROPEAN JOURNAL, WILEY-VCH VERLAG GMBH & CO. KGAA, WEINHEIM, DE, vol. 13, no. 34, 1 January 2007 (2007-01-01), pages 9534-9541, XP002484787, ISSN: 0947-6539, DOI: 10.1002/CHEM.200701057 page 9537, column 2, line 1 - line 29; table 1; compound 6</p>	1, 11
X	<p>wo 2008/ 106080 A2 (UNIV PITTSBURGH [US]; WILF PETER [US]; WANG ZHIYONG [US]) 4 September 2008 (2008-09-04) claims 38, 39; compound XV</p>	1, 11
X	<p>wo 2009/ 134279 A1 (UNIV CALIFORNIA [US]; ELLMAN JONATHAN A [US]; PATTERSON ANDREW W [US];) 5 November 2009 (2009-11-05) claim 7; compounds 6, 10</p>	1, 11
X	<p>EP 2 292 639 A1 (KEMOTECHE S R L [IT]) 9 March 2011 (2011-03-09) claims 10, 21-23</p>	1, 11
X	<p>wo 2014/040752 A1 (ONTOCHEM GMBH [DE]) 20 March 2014 (2014-03-20) claims 1, 14; compounds 0C501, 0C509</p>	1, 11
X	<p>wo 2012/010287 A1 (LEIBNIZ INSTITUT FÜR PFLANZENBIOCHEMIE [DE]; WESSJOHANN LUDGER A [DE]; PA) 26 January 2012 (2012-01-26) claims 7, 13; compound H</p>	1, 11
	-/-	

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2015/059807

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category"	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	wo 2008/ 13856 1 AI (R & D BIOPHARMACEUTICALS GMBH [DE] ; RICHTER WOLFGANG [DE]) 20 November 2008 (2008- 11-20) claims 1, 14, 15; tabl e 1; compounds RD259, RD282, RD305, RD291, RD311, RD321, RD330 -----	1, 11
X	wo 2013/085925 AI (IGENICA INC [US] ; JACKSON DAVID Y [US] ; HA EDWARD [US]) 13 June 2013 (2013 -06- 13) claim 47 -----	1
X	wo 2009/055562 AI (ENDOCYTE INC [US] ; VLAHOV IONTCHO RADOSLAVOV [US] ; WANG YU [US] ; LEAM0) 30 April 2009 (2009 -04-30) compound s EC0386 , EC0550 -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2015/059807

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
wo 2014126836 AI	21-08-2014	AU 2014216539 AI	01-10-2015
		CA 2900854 AI	21-08-2014
		CN 105073139 A	18-11-2015
		EA 201591317 AI	30-12-2015
		EP 2956173 AI	23-12-2015
		KR 20150119086 A	23-10-2015
		TW 201443083 A	16-11-2014
		US 2014227295 AI	14-08-2014
		US 2014227298 AI	14-08-2014
		US 2015132324 AI	14-05-2015
		UY 35322 A	29-08-2014
		wo 2014126836 AI	21-08-2014
wo 2011017249 AI	10-02-2011	AR 077701 AI	14-09-2011
		AU 2010279674 AI	23-02-2012
		CA 2770042 AI	10-02-2011
		CN 102725001 A	10-10-2012
		CN 104592351 A	06-05-2015
		CO 6501196 A2	15-08-2012
		DK 2461830 T3	12-01-2015
		EA 201270242 AI	30-07-2012
		EP 2461830 AI	13-06-2012
		ES 2525351 T3	22-12-2014
		HK 1164751 AI	16-01-2015
		HR P20140976 TI	02-01-2015
		JP 2013501055 A	10-01-2013
		KR 20120047998 A	14-05-2012
		NZ 597985 A	30-08-2013
		PE 10872012 AI	17-08-2012
		PT 2461830 E	11-12-2014
		SG 178095 AI	29-03-2012
		SI 2461830 TI	30-01-2015
		SM T201400183 B	15-01-2015
		TW 201106976 A	01-03-2011
		US 2011027274 AI	03-02-2011
		US 2013189256 AI	25-07-2013
		US 2013197259 AI	01-08-2013
		US 2013204033 AI	08-08-2013
		US 2014323690 AI	08-10-2014
		wo 2011017249 AI	10-02-2011
wo 2008106080 A2	04-09-2008	US 2010047841 AI	25-02-2010
		wo 2008106080 A2	04-09-2008
wo 2009134279 AI	05-11-2009	US 2011021568 AI	27-01-2011
		wo 2009134279 AI	05-11-2009
EP 2292639 AI	09-03-2011	CA 2710693 AI	22-01-2011
		EP 2292639 AI	09-03-2011
		ES 2524800 T3	12-12-2014
		JP 2011037846 A	24-02-2011
		US 2011200581 AI	18-08-2011
wo 2014040752 AI	20-03-2014	AU 2013314625 AI	16-04-2015
		CA 2882814 AI	20-03-2014
		CN 104755105 A	01-07-2015
		EP 2708243 AI	19-03-2014
		EP 2895196 AI	22-07-2015

INTERNATIONAL SEARCH REPORT

Information on patent Family members

International application No

PCT/US2015/059807

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		JP 2015531794 A	05-11-2015
		US 2015238626 AI	27-08-2015
		WO 2014040752 AI	20-03-2014

wo 2012010287	AI 26-01-2012	AU 201 1281939 AI	21-02-2013
		CA 2803948 AI	26-01-2012
		EP 2409983 AI	25-01-2012
		EP 2596008 AI	29-05-2013
		ES 2534068 T3	17-04-2015
		JP 201353617 1 A	19-09-2013
		US 20132 17638 AI	22-08-2013
		WO 2012010287 AI	26-01-2012

wo 200813856 1	AI 20-11-2008	CA 272367 1 AI	20-11-2008
		EP 2148886 AI	03-02-2010
		EP 2532673 A2	12-12-2012
		ES 2463693 T3	29-05-2014
		US 2012 129779 AI	24-05-2012
		WO 2008 13856 1 AI	20-11-2008

wo 2013085925	AI 13-06-2013	AU 20123480 17 AI	03-07-2014
		CA 2857398 AI	13-06-2013
		CN 1042447 18 A	24-12-2014
		EP 2793585 AI	29-10-2014
		HK 1203309 AI	30-10-2015
		JP 2015500287 A	05-01-2015
		KR 20140 139480 A	05-12-2014
		PH 12014501229 AI	08-09-2014
		SG 11201402686U A	27-06-2014
		US 2013224228 AI	29-08-2013
		WO 2013085925 AI	13-06-2013

wo 2009055562	AI 30-04-2009	AU 20083 16835 AI	30-04-2009
		CA 270349 1 AI	30-04-2009
		CN 10190944 1 A	08-12-2010
		EP 2209374 AI	28-07-2010
		IL 205253 A	30-07-2015
		JP 201 1500835 A	06-01-2011
		JP 2014240387 A	25-12-2014
		US 201024070 1 AI	23-09-2010
		WO 2009055562 AI	30-04-2009
